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1 Introduction 
Pain is defined as “an unpleasant emotional experience associated with actual or potential 
tissue damage, or described in terms of such damage” (International Association for the Study 
of Pain, 1979).  
 
The physiological consequences of pain involve endocrine and sympathetic 
nervous system activation (Gaynor and Muir, 2009). Non-adequately treated or untreated 
pain in animals in clinical settings is known to cause suffering, a decrease in immunity, 
and an increase in morbidity and mortality (Silverstein, 2009). Furthermore, constant pain 
can alter the pain transmission, modulation and perception, which can result in peripheral 
and central sensitization (Woolf, 2011). The main receptor responsible for central 
sensitisation at the level of the spinal cord is the N-methyl-D-aspartate (NMDA) receptor. 
This receptor is activated by the neurotransmitter glutamate and glycine. Magnesium is a 
natural antagonist on the NMDA receptor as the magnesium ion (Mg2+) blocks the central 
canal of the ionic receptor inhibiting calcium influx and preventing neuronal 
depolarisation (Mayer et al., 1984; Petrenko et al., 2003). 
 
Based on the Mg2+ interaction on the NMDA-receptor several investigations have 
focused on a possible analgesic effect mediated by systemic administration of 
magnesium.  
 
The majority of studies in humans showed a decrease in inter- and postoperative 
opioid requirements in patients undergoing soft tissue and orthopaedic surgeries (Koinig 
et al., 1998; Kara et al., 2002; Unlügenç et al., 2003; Hwang et al. 2009; Kogler, 2009; 
Gupta et al., 2011; Kiran et al., 2011).  However, other studies found no beneficial effect 
of magnesium
 
when administered
 
systemically to human patients undergoing soft tissue 
surgery (Wilder-Smith et al., 1998; Zarauza et al., 2000; Ko et al., 2001; Tramèr and 
Glynn 2007; Sullivan et al., 2012). In a systematic review of 14 human randomized 
clinical trials, it was concluded that there was no effect of systemic administration of 
magnesium on post-operative pain intensity and analgesic requirements (Lysakowski et 
al., 2007). 
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Only a few studies have investigated the effect of systemic magnesium
 
administration in animals. Systemic administration of magnesium reversed mechanical 
hyperalgesia induced by magnesium deficiency (Begon et al., 2001) and reduced 
allodynia in rats (Xiao and Bennett, 1994). However, intravenous administration of 
magnesium
 
failed to show a clear antinociceptive effect in dogs undergoing 
ovariohysterectomy (Rioja et al., 2012).  
 
The main site of magnesium
 
action is at the level of the spinal cord, but the ability 
of serum magnesium to cross the blood-brain barrier remains unclear (McCarthy et al., 
1998; Ko et al., 2001). Therefore, the neuraxial administration of magnesium has been 
investigated in human studies and animal trials. 
 
Epidural and intrathecal administration of analgesic drugs, such as local 
anaesthetics and opioids, in humans and in animals are commonly used methods to 
achieve multimodal analgesia and anaesthesia (Grass, 2000; Valverde, 2008). The 
benefits of neuraxial administration include less systemic absorption, using lower doses, 
longer duration of the effects, which leads to fewer side effects and a superior analgesic 
effect compared to systemic administration of analgesic drugs (Bonath, 1986; Valverde, 
2008). However, when local anaesthetics are administered neuraxially, this results in 
motor paralysis (Tranquilli, et al., 2007) which may be undesirable. The administration of 
opioids in combination with other drugs that do not cause motor paralysis, such as 
magnesium, has been investigated. 
 
In rats, magnesium administered intrathecally enhanced spinal anaesthesia 
induced by opioids (Kroin et al., 2000) and delayed the development of opioid tolerance 
(McCarthy et al., 1998). Furthermore, intrathecal magnesium in rats induced sedation and 
sensory block (Bahar et al., 1996) and motor block (Karasawa et al., 1998). The addition 
of magnesium
 
to epidural local anaesthetics or ketamine induced a prolonged analgesic 
effect in goats (Bigham et al., 2009), horses (Bigham and Shafiei, 2008), cattle (Dehghani 
and Bigham, 2009b) and sheep (DeRossi et al., 2012). 
 
In human clinical trials, magnesium administered epidurally or intrathecally in 
combination with opioids and/or local anaesthetics provides a longer duration of 
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analgesia (Buvanendran et al., 2002; Ozalevli et al., 2005; Yousef and Amr, 2010; Shukla 
et al., 2011; Nath et al., 2012), a post-operative opioid sparing effect (Arcioni et al., 
2007; Ouerghi et al., 2011; Khezri et al., 2012) and a decrease in post-operative pain 
scores (Sun et al., 2012) in patients undergoing soft tissue and orthopaedic surgeries. 
However, epidural administration of magnesium showed no effect on postoperative pain 
and analgesia requirement in paediatric patients undergoing surgery (Birbicer et al., 2007) 
 
The purpose of this study was to determine whether lumbosacral epidural 
administration of magnesium would have an antinociceptive effect on its own and 
whether it would enhance morphine antinociception in dogs. It was hypothesised that 
magnesium
 
would produce an antinociceptive effect when administered alone and that it 
would enhance morphine antinociception when administered in combination. 
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2 Literature review 
2.1 Pain 
2.1.1 The definition of pain 
The International Association for the Study of Pain defines pain as “an unpleasant emotional 
experience associated with actual or potential tissue damage, or described in terms of such 
damage” (International Association of the study of Pain, 1979). 
 
Pain occurs as a conscious awareness of discomfort resulting from injury, disease 
or emotional stress. A series of complex neurophysiologic processes are involved in 
creating the experience of pain. These neurophysiologic processes can be divided into 
four distinct components: transduction, transmission, modulation and perception. The 
biological function of pain is to warn the individual of a harmful situation and to avoid 
tissue damage by leading to motor action and a change in behaviour, which results in 
avoiding, escaping or destroying the factors responsible for the nociceptive stimulus 
(Gaynor and Muir, 2009). 
 
Pain of high intensity or longer duration can alter the neurophysiologic processes 
and induce peripheral and central sensitisation which could result in pathological pain. 
Pathological pain has no biological advantage for the animal and can be seen as a disease 
on itself (Woolf and Ma, 2007).  
 
Animals are unable to verbally communicate the pain experience; therefore, the 
assessment of pain in animals is challenging. However, there is scientific evidence that all 
vertebrates and some invertebrates can experience pain but the way pain is experienced 
and expressed depends on the degree of development of the central and peripheral 
nervous systems (Gaynor and Muir, 2009). Nevertheless, the uncertainty about the 
presence, quality and intensity of the pain experience by animals does not preclude the 
administration of adequate pain treatment (Hellyer, 2004). 
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Over the last decades, the understanding of pain and its appropriate treatment 
have been improved and pain management is becoming more and more an important 
component of good medical practice in human and veterinary medicine (Dohoo and 
Dohoo, 1996; Hellyer, 2002). 
 
In human medicine, the Joint Commission on Accreditation of Healthcare 
Organisations (JCAHO) elevated pain to the fifth vital sign (together with temperature, 
respiration, pulse and blood force) in 2000. They state that “appropriate pain management 
is good medicine because it results in quicker clinical recovery; shorter hospital stays, 
fewer readmissions, and improved quality of life, leading to increased productivity” 
(Phillips, 2000). 
 
In 2003, the American Animal Association followed the JCAHO’s guideline and 
elevated pain to the fourth vital sign (along with temperature, pulse and respiration). The 
American College of Veterinary Anaesthesiologist (ACVA) acknowledged in their 
position paper on the treatment of animal pain (1998) that “animal pain is a clinically 
important condition that adversely affects an animal’s quality of life”. Furthermore, they 
state that “the prevention and alleviation of animal pain is an important and tenable 
therapeutic goal in veterinary medicine”. Therefore, veterinarians are morally and 
medically obligated to address pain in animals and to avoid, assess and treat pain in their 
patients (Hellyer, 2002). 
 
2.1.2 Peripheral nociception 
The experience of pain involves a series of complex neurophysiologic processes, which 
can be divided into four distinct components: transduction, transmission, modulation and 
perception (Gaynor and Muir, 2009). In this chapter the process of transduction will be 
discussed. 
 
Transduction is the transformation of a noxious stimulus into an electrical signal 
in a sensory nerve ending. Free nerve endings can respond to both low-intensity (non-
painful) and high-intensity (painful) stimuli. Only the nerve endings that respond to high-
Literature review  
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threshold stimuli are called nociceptors. Nociceptors can be found in skin, muscle, joints, 
periosteum and viscera. The type of noxious stimuli that the nociceptors can detect are 
thermal, chemical or mechanical stimuli or a combination of the three (Stoelting and 
Hillier, 2005). 
 
In normal tissue, nociceptors are inactive until a noxious stimulus, exceeding the 
threshold of excitation, activates them and as a consequence an electrical excitatory signal 
(action potential) is generated and transmitted to the dorsal horn of the spinal cord 
through the nerve fibre (Stoelting and Hillier, 2005). The greater the intensity of the 
stimulus, the greater the number of electrical signals that are generated by the free nerve 
ending. Also, a stimulus of long duration produces a prolonged electrical signal (Gaynor 
and Muir, 2009).  
 
The nerve fibres are divided on the basis of their conduction velocity into Aα, 
Aβ, Aδ and C-fibres, in order of greatest to lowest conduction velocity. Aα and Aβ-fibres 
are low-threshold fibres and respond to mechanical stimuli. These fibres are regarded as 
the ones responsible for transducing innocuous sensory information. Aδ-fibres can be 
nociceptors or not depending on their threshold of excitation. Approximately 25% of the 
Aδ-fibres are nociceptors (Gaynor and Muir, 2009) and aproximately 85% of the C-fibres 
are nociceptors (Gaynor and Muir, 2009).  
 
The Aδ-fibre nociceptors can be sub-divided into three groups depending on the 
type of activating stimulus: high-threshold mechano nociceptors, mechano-heat 
nociceptors and mechano-cold nociceptors. The mechano-heat nociceptors are further 
divided into Type I and Type II (Djouhri and Lawson, 2004). Type I mechano-heat 
nociceptors have a higher heat threshold and a lower mechanical threshold than Type II. 
Type I mechano-heat nociceptors can also respond to chemical stimuli. Therefore, these 
Aδ-fibres can be referred to as polymodal nociceptors (Djouhri and Lawson, 2004. 
 
The excitatory signals in Aδ-fibres are transmitted with a high discharge and a 
rapid conduction velocity (12 to 30 m/s) due to their myelinated axon. The activation of 
these fibres is responsible for the pricking sharp sensation associated with the initiation of 
pain (Tranquilli et al, 2007). 
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The C-fibre nociceptors are mostly high-threshold fibres that respond to more 
than one type of stimuli and they can also be referred to as polymodal. They are 
unmyelinated and respond with slow conduction velocities of 0.5 m/s to 2 m/s. The 
activation of these nociceptors is associated with a slow and burning type of pain, which 
is poorly localised and less specifically related to the stimulus (Stoelting and Hillier, 
2005). 
 
Silent nociceptors are nociceptors with a high threshold of excitation that are 
normally not activated (Woolf and Ma, 2007). C and Aδ-fibres can be silent nociceptors. 
However, this threshold can be reduced by tissue-inflammatory mediators such as 
prostaglandins and leukotrienes, which will lead to activation of these silent nociceptors 
in the presence of massive tissue inflammation. It is presumed that their activation is one 
mechanism for primary hyperalgesia, also called peripheral sensitisation (Woolf and Ma, 
2007). 
 
2.1.3 Central nociception 
Central nociception consists of the neurophysiologic processes of transmission, 
modulation and perception in the central nervous system (CNS) (Stoelting and Hillier, 
2005). 
 
Central nociception commences when the primary afferent nerve fibres enter the 
spinal cord. The spinal cord is divided into white matter formed by the axons from 
projection neurons and grey matter formed by the cell bodies (Gaynor and Muir, 2009). 
The grey matter contains interneurons also known as gate cells and cell bodies from 
ascending neurons. The grey matter is divided into three anatomic regions: the dorsal 
horn, the intermediate zone and the ventral horn. Sensory information is received, 
transmitted and modulated in the dorsal horn (Gaynor and Muir, 2009).  
 
The grey matter is further subdivided into ten Laminae based on similar function 
of the neuronal cells. Laminae I to VI are located in the dorsal horn and participate in 
pain transmission and modulation (Gaynor and Muir, 2009). 
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Lamina I plays an important role in pain sensation. It receives sensory input 
mostly from Aδ-fibres in the skin, musculoskeletal system and viscera and contains 
specific nociceptive neurons, wide-dynamic range neurons as well as interneurons. 
Lamina II is also known as substantia gelatinosa and is composed of mostly C-fibres and 
a large number of interneurons. Lamina II integrates sensory information together with 
Lamina I. Due to the large number of interneurons in Lamina II, it is believed that this 
lamina plays a key role in the transmission and modulation of pain. Laminae III to VI, 
also known as nucleus proprius, receive tactile, thermal and mechanical sensory 
information from the periphery and furthermore they receive descending information 
from the brain. Lamina X is located around the central canal of the spinal cord and 
receives and transmits sensory information to the brain. Finally, Laminae VII to IX are 
located in the intermediate and ventral zones of the spinal cord and are not involved in 
pain transmission (Gaynor and Muir, 2009). 
 
The primary sensory neurons enter the spinal cord through the dorsal root, where 
they synapse with secondary afferent neurons. Two different types of secondary afferent 
neurons are described: nociceptive specific neurons and second-order wide dynamic 
range neurons (Tranquillie et al. 2007). Nociceptive specific neurons are dedicated purely 
to nociceptive stimuli and in consequence the ascending stimulus results in a more 
discriminative nociception. In contrast, wide dynamic range neurons are stimulated by 
noxious and non-noxious sensory stimuli and as a result the conveyed nociception is less 
discriminative. The wide dynamic range neurons are also characterised by reacting to 
afferent noxious stimuli from the skin and the viscera and this results in the phenomenon 
of “referred pain”. Referred pain occurs when a noxious stimulus received from the 
viscera is perceived as having originated in the skin (Tranquillie et al. 2007). 
 
Interneurons play an important role in modifying and regulating sensory 
information. Melzack and Wall in 1965 developed a concept of pain modulation in the 
spinal cord that they called “the gate control theory” (Melzack and Wall, 1965), although 
this theory seems to be somewhat inaccurate, it is still used to understand the modulation 
of pain. This theory implies that afferent sensory impulses from nerve fibres entering the 
spinal cord underline a modulating feedback in the substantia gelatinosa mediated by 
interneurons. Nociceptive C- and Aδ-fibres and non-nociceptive A-fibres connect with 
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wide dynamic range neurons. The non-nociceptive neurons additionally synapse with 
interneurons and the interneurons have inhibitory properties on the wide dynamic range 
neurons. This results in less activation of the wide dynamic range neurons and 
subsequently of the projection neurons. Summarising, non-nociceptive nerve impulses 
“close the gate” for nociceptive stimuli (Melzack and Wall, 1965). 
 
The transmission and modulation of pain perception in the spinal cord is regulated 
by a multitude of neurotransmitters. They can be divided into excitatory, inhibitory and 
facilitating neurotransmitters. The most important neurotransmitters are amino acids. The 
dicarboxylic amino acids glutamate and aspartate are the most important excitatory 
neurotransmitters while the monocarboxylic amino acids like gamma-aminobutyric acid 
(GABA), glycine and alanine act as inhibitory neurotransmitters (Gaynor and Muir, 2009).  
 
Glutamate and aspartate have excitatory effects and they act on multiple receptor 
subtypes. The receptors are subdivided into ionotropic receptors (i.e. ligand-gated ion 
channels) and metabotropic receptors (i.e. G-protein coupled receptors). The ionotropic 
receptors are named according to their specific agonists in vitro. Subsequently ionotropic 
receptors can be divided into: NMDA-receptors, α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid-receptors (AMPA) and kainate-receptors (Zimmermann, 2004).  
 
The NMDA-receptor is the main receptor in terms of transmission of nociceptive 
stimuli by afferent neurons in the central nervous system and is widely spread at the level 
of the spinal cord and the brain (Petrenko et al., 2003). The excitatory transmitter 
glutamate binds to the NMDA-receptor site and the co-transmitter glycine binds to the 
modulatory site of the receptor. Both binding sites must be occupied for the channel to 
open. The activation of the NMDA-receptor results in an influx of calcium ion causing 
post-synaptic depolarisation and triggering a cascade of events including activation of the 
protein kinases (Petrenko et al., 2003). Mayer et al. discovered in 1984 that the NMDA 
receptor is normally occupied by Mg2+ at physiological extracellular concentrations, 
which causes blockade of the ion channel, and that this Mg2+ block is voltage dependant 
(Mayer et al., 1984). Mayer et al. also showed that a decrease in the extracellular Mg2+ 
concentration results in a reduction of the voltage-sensitivity of the receptor (decreased 
voltage-threshold of activation). This activation of the NMDA-receptor caused by Mg2+ 
deficiency induces a state of hyperalgesia (Begon et al., 2001). Several exogenous 
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antagonists of this receptor are known. The anaesthetic and analgesic action of ketamine 
is attributable to its antagonistic effect on this receptor (Petrenko et al., 2003). 
 
The NMDA-receptor consists of three subunits: NR1, NR2 (types A, B, C and D) 
and NR3 (types A and B). At least the subunit NR1 and one of the NR2 subunits are 
required to form the receptor. Different types of subunits NR2 have been shown to 
influence the pharmacological properties of the receptor. The affinity for agonist and 
antagonist drugs is determined by the type of subunits forming the receptor. The 
sensitivity for blockade by Mg2+ is also influenced by the subunits type and it is 
exaggerated by type NR2A and NR2B (Petrenko et al., 2003). The NR3 subunit can be 
co-expressed and influences the receptor activity. When this subunit is present, the 
receptor turns into an excitatory glycine receptor, unaffected by glutamate, impermeable 
to calcium and resistant to Mg2+ block. The role of the NR3 subunit on the pain 
mechanism has not been investigated yet (Petrenko et al., 2003). 
 
The NMDA-receptor does not participate in normal pain transmission as it is 
normally blocked by Mg2+ (Figure 1). Constant afferent input alters the NMDA-receptor 
properties mediated by the protein kinase C (PKC) and the tyrosin kinase, resulting in 
removal of the Mg2+ block; therefore, calcium influx occurs (Figure 2). The increase in 
postsynaptic calcium concentration leads to a PKC activation and thus exponentiation of 
the NMDA-receptor response due to phosphorylation (Figure 3) (Petrenko et al., 2003). 
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Figure 1: Normal synaptic transmission: Presynaptic calcium influx through voltage 
sensitive calcium channel (VSCC) results in glutamate release. Glutamate activates 
AMPA-receptors leading to sodium influx into the postsynaptic dorsal horn neuron 
extrapolated from, Petrenko et al., 2003.  
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Figure 2: Constant afferent input leads to constant presynaptic Calcium influx. glutamate 
and substance P (SP) release increase. SP leads to neurokinin 1 receptor activation 
(NK1R), whereas glutamate activates AMPA-receptors leading to Sodium influx into the 
postsynaptic dorsal horn neuron. The depolarisation of the postsynaptic membrane leads 
to removal of the Mg2+ block of the NMDA-receptors and calcium influx occurs. NMDA-
receptor becomes activated and facilitate the response extrapolated from, Petrenko et al., 
2003.  
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Figure 3: Calcium influx leads to posttranslational modification of the NMDA-receptor, 
where PKC phosphorylates the NMDA-receptor leading to a prolonged channel opening 
time and decrease in voltage dependent Mg2+ block extrapolated from, Petrenko et al., 
2003.  
 
 
Pain projection at the level of the spinal cord includes multiple nociceptive 
pathways and their functions are overlapping and complex (Tranquilli et al. 2007). The 
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The ascending information from the spinoreticular tract terminates in the reticular 
formation. This area is composed of cores (most important is the raphe nucleus) 
extending from the medulla oblongata to the diencephalon and is involved in 
consciousness as well as mediation of sensory, autonomic and motor functions (Gaynor 
and Muir, 2009). The reticular formation sends collaterals to other nuclei which are 
located in the brainstem, hypothalamus, thalamus and cerebral cortex (Lamont et al., 
2000).  
 
The hypothalamus is responsible for processing sensory and hormonal 
information (Desborough, 2000). It plays a key role in emotional reactions and vegetative 
responses. Activation of the hypothalamus leads to sympathetic nervous system and 
pituitary responses causing the release of catecholamines and glucocorticoids. 
 
The limbic system contains cores in the cortical and subcortical regions. Some 
autonomic functions such as thermoregulation and respiration are controlled in this area 
in addition to emotional responses composed of physiological, cognitive and behavioural 
changes (Tranquilli et al. 2007). Deregulation or over activity of the limbic system can 
lead to aggression, fear, anxiety or depression (Silverstein, 2009). 
 
The cerebral cortex performs the higher neurological functions and nociception in 
this area is described as cognitive-evaluative, which is affected by experience, learning, 
attention and memory. Complex behaviour patterns are attributable to this structure 
(Tranquilli et al. 2007). 
 
The perception of pain is also dependant on the activation of the descending pain 
pathway. The periaqueductal grey matter (PAG) is a core of grey matter located in the 
midbrain and is a key structure in ascending and descending control of sensory 
information (Lamont et al., 2000). The PAG receives input from higher brain centres 
such as the cerebral cortex, the limbic system and the hypothalamus. The PAG is known 
to have a high density of opioid receptors and its stimulation results in release of 
endogenous opioids and enkephalins (Tranquilli et al. 2007). 
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The PAG synapses with the nucleus raphe magnus located in the reticular 
formation, from which adrenergic and serotonergic nerves descend to the spinal cord and 
transmit inhibitory signals mediated by the PAG. The endogenous release of opioids can 
induce inhibitory and analgesic effects in the brain and at the level of the spinal cord 
(Lamont, 2008).  
 
2.1.4 Classification of pain 
Pain can be categorized based on different aspects, such as according to underlying 
disease (e.g. arthritis, cancer), anatomy (e.g. back, orthopaedic), general region (e.g. 
superficial, deep), duration (e.g. acute, chronic) and intensity (mild, moderate, severe) 
(Gaynor and Muir, 2009). However, these categories are purely descriptive and they do 
not explain the underlying mechanism responsible for the pain. Additionally, these 
categories do not provide any therapeutic advice. 
 
Amongst experts, pain is categorised most often according to the mechanism 
responsible for its production.  
 
One common classification of pain is into physiological pain, caused by noxious 
stimuli, pathophysiological pain, caused by a change in organ function (e.g. due to 
inflammation) and neuropathic pain, caused by damage of the nervous system (Pfannkuche, 
2008). 
 
Another classification of pain is into nociceptive pain and neuropathic pain. 
Nociceptive pain is further subdivided into visceral pain and somatic pain. Visceral pain 
is described as diffuse, poorly localized and often causing autonomic nervous system 
activation. Somatic pain originates from the skin and musculoskeletal system and is 
characterized as a sharp, pricking and well-localized pain. Neuropathic pain involves 
damage of the peripheral or central neural pathways and it is described as a burning type 
of pain (Stoelting and Hillier, 2005). 
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Woolf classified pain into adaptive and maladaptive pain based on its biological 
function (Woolf, 2010). Adaptive pain includes nociceptive pain and inflammatory pain. 
Nociceptive pain functions as a warning system and evokes an immediate response such 
as a withdrawal reflex, allowing the animal to avoid the potential damaging stimuli 
(Figure 4).  
 
Figure 4: Nociceptive pain extrapolated from, Woolf, 2010. 
 
Inflammatory pain is also adaptive and protective and appears after tissue 
damage. It leads to an increase in sensitivity and results in decreased movement and 
avoidance of further damage of the tissue, thereby promoting and assisting the healing 
process (Figure 5).  
 
Figure 5: Inflammatory pain extrapolated from, Woolf, 2010. 
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stimuli (e.g. touch), which induces an exaggerated and excessive response in the nervous 
system (Figure 6).  
 
Figure 6: Pathological pain extrapolated from, Woolf, 2010. 
 
From a therapeutic point of view, Woolf’s classification of pain seems to be the 
most useful. 
 
Neuropathic pain originates from injury of the nervous system and neuroplastic 
changes in it (Woolf, 2000). Neuropathic pain has no biological advantage. The 
underlying pathophysiological mechanism is not clearly understood, but a lack of 
modifiability and plasticity of the nervous system is considered to be responsible (Woolf, 
2010; Tranquilli et al., 2007). 
 
 Peripheral sensitisation occurs due to a change in the chemical milieu resulting 
from the disruption of cells, secretions of inflammatory cells, mast cells degranulation 
and induction of enzymes (Woolf and Ma, 2007). A variety of substances have been 
identified but new substances are still being identified. Well-studied substances are 
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kinins, amines, prostaglandins, cytokines, chemokines and growth factors. This so-called 
“inflammatory soup” causes a decrease of the nociceptor threshold of activation and leads 
to an exaggerated response to noxious stimuli (Woolf and Ma, 2007). These changes 
result in a condition called “primary hyperalgesia” (Tranquilli et al., 2007). Furthermore, 
silent nociceptors, with are normally inactive, are also recruited and innocuous stimuli 
start being sensed as noxious (Woolf and Ma, 2007). The hyperexcitability of the 
nociceptors induces spontaneous depolarisations originating in the axon or in the cell 
body in the absence of a sensory stimulus. This change in sensitivity can lead to 
spontaneous pain in the absence of any noxious stimulus (Woolf and Ma, 2007). This 
condition is termed “allodynia” (International Association for the Study of Pain, 1979). 
 
Central sensitisation is triggered by a high discharge rate and long duration of 
excitatory input in the spinal cord (Woolf, 2011). It is characterized by an increased 
synaptic efficacy that lasts longer than the duration of the conditioning stimulus. This 
excitatory input leads to synaptic plasticity characterised by changes in the microglia, gap 
junctions, membrane excitability and gene transcription. The threshold, kinetics and 
activation of the receptors and nerve terminals in the spinal cord change, resulting in an 
increase in pain transmission and perception (Woolf, 2011). The NMDA-receptor has 
been shown to play a key role in the central sensitization process (Petrenko et al., 2003; 
Zimmermann, 2004). In normal synaptic transmission, the post-synaptic NMDA-receptor 
is voltage-dependently blocked by extracellular Mg2+. The increased excitatory input 
leads to post-synaptic depolarisation mediated by glutamate, which results in sodium 
influx through the AMPA-receptor. A strong and prolonged post-synaptic depolarisation 
reduces the voltage-dependent Mg2+ block of the NMDA-receptor. Calcium influx 
through the NMDA-receptor into the postsynaptic cells occurs. Additionally, intracellular 
calcium leads to activation of the PKC and this mediates an enhanced opening of the 
NMDA-receptor. Pre-synaptic NMDA-receptors have also been identified. Their 
activation results in substance-P release, enhancing the excitatory transmission at the 
level of the post-synaptic membrane (Petrenko et al., 2003). These changes result in a 
condition called “secondary hyperalgesia” (Woolf, 2011). 
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Peripheral and central sensitisation, which lead to primary and secondary 
hyperalgesia and may also result in allodynia, are likely to play an important role in the 
development of neuropathic pain (Woolf, 2011). 
 
The term “wind up” is used to describe the central plasticity stimulated by a 
constant and rapid activation of C-fibres, which leads to an increase in action potential 
firing over the course of stimulus (Tranquilli et al., 2007). Wind up has been associated 
with activation of the NMDA-receptor (Gaynor and Muir, 2009). 
 
Central sensitisation and “wind up” result in pain perception causing continuing 
and severe pain (Gaynor and Muir, 2009). 
 
2.1.5 Physiological consequences of pain 
The physiological effects of pain on the body are multiple and they aim to protect and 
prepare the organism against the insult by mobilising energy sources. Pain results in 
behavioural modulation, activation of the sympathetic and neuroendocrine systems 
(Gaynor and Muir, 2009) as well as immunological and haematological changes. The 
physiological changes caused by injury and trauma are referred to as stress response 
(Desborough, 2000).  
 
The behavioural modulation depends on the species and comprises both a learned 
and a memory component. Behavioural changes often seen in dogs during pain and fear 
are avoidance, immobility and aggressive behaviour. The goal is to avoid and escape 
tissue damage and to maintain homeostasis (Gaynor and Muir, 2009). The learned and 
memory components are processed in the cerebral cortex (Tranquilli et al., 2007), while 
the limbic system and the hypothalamus are responsible for the fear and anxiety, as well 
as the behavioural response (Tranquilli et al., 2007).  
 
The main change in endocrine function is caused by the neuroendocrine axis and 
the activation of the sympathetic nervous system. Afferent impulses stimulate the 
secretion of corticotrophin releasing factor (CRF) and vasoactive intestinal peptide by the 
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hypothalamus, which leads to an increase in pituitary secretion of adrenocorticotropin 
hormone (ACTH), propriomelanocortin, growth hormone, vasopressin and prolactin. 
Propriomelanocortin is the link substrate between the pituitary-adrenal axis and the 
endogenous opioid system. Propriomelanocortin is metabolised to ACTH and β-
endorphine. Additionally, CRF stimulates catecholamine and endogenous opioid release 
from the adrenal medulla (Tsigos and Chrousos, 2002).  
 
Adrenocorticotropic hormone increases the release of glucocorticoids, in 
particular cortisol, from the adrenal cortex. Cortisol is known as the key mediator of the 
stress response. It creates a catabolic state by stimulating gluconeogenesis, increasing 
protein breakdown, enhancing the sensitivity of fat tissue towards the action of lipolytic 
hormones and causing insulin resistance. The consequence of these effects is to ensure 
glucose delivery to the brain and to provide energy sources. The ability of cortisol to 
stimulate the adrenomedullary secretion of catecholamines enhances the stress response 
and aids in maintaining cardiovascular stability. A negative feedback is mediated from 
the glucocorticoids on ACTH production but it seems to be ineffective in trauma due to 
surgery (Desborough, 2000). Another beneficial effect of cortisol is to prevent an 
overreaction of the immune system by inhibiting the migration of macrophages and 
neutrophils into inflamed tissue and by decreasing the amount of inflammatory mediators 
such as prostaglandins (Tsigos and Chrousos, 2002). There is a direct relationship 
between the amount of ACTH and cortisol release and the degree of trauma (Weissmann, 
1990). 
 
The additional release from the pituitary gland of growth hormone, vasopressin 
and prolactin contribute in different ways to the hormonal changes that occur due to the 
stress response (Desborough, 2000). 
 
Growth hormone also known as somatostatin is secreted from the anterior 
pituitary. Most of the effects are manifested through increased transcription of the insulin-
like growth factors in a variety of tissues. Insulin-like growth factor creates an anabolic 
effect by enhancing protein synthesis, inhibiting protein breakdown, promoting lipolysis 
and it also has an anti-insulin effect. As a result, the plasma becomes hyperglycaemic and 
the glucose dependent tissues (e.g. brain) can be adequately supplied (Desborough, 
2000). Different studies have shown that there is a decrease in insulin and an increase in 
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glucagon related to surgeries. The major effect is an increase in gluconeogenesis 
(Weissman, 1990).  
 
Vasopressin is also known as antidiuretic hormone. Its secretion is stimulated by 
changes in plasma osmolality and also influenced by changes in blood force and blood 
volume during stress and fear (Weissman, 1990). Vasopressin activates the vasopressin-2 
receptors in the renal tubules causing an increase in number of aquaporin water channels. 
Renin is secreted from the juxtaglomerular cells and angiotensin II production increases, 
which leads to a release of aldosterone. Aldosterone leads to increased water reabsorption 
due to Na+ reabsorption in the kidney. The main effect of vasopressin and aldosterone is 
an increase in water absorption and thereby a stabilisation of the body fluid volume 
(Desborough, 2000).  
 
The activation of the sympathetic nervous system results in release of adrenaline 
by the adrenal medulla. Additionally, noradrenaline is released from the sympathetic 
nerve terminals and spills over into the plasma. The major catecholamine effects are 
related to the cardiovascular system causing tachycardia, hypertension, an increase in 
cardiac output, with a consequent increase in myocardial oxygen consumption, to provide 
adequate perfusion to the body tissues and organs (Tsigos and Chrousos, 2002). 
Additionally, adrenaline increases gluconeogenesis, glycogenolysis and lipolysis, 
decreases insulin release and causes peripheral insulin resistance (Weissman, 1990). The 
increase in ventilation and heart rate due to the sympathetic response can cause major 
problems in patient with compromised cardiovascular function, when they are not able to 
compensate (Weissman, 1990). 
 
Damaged tissue due to injury or infection leads to activation of cytokines. This 
group of proteins include the interleukins and the tumour necrosis factors. They are 
produced from leucocytes, fibroblasts, macrophages, monocytes and endothelial cells and 
play a major role in the acute inflammatory response. Their local effects include 
chemotaxis, which stimulates migration of lymphocytes, monocytes and neutrophils to 
inflamed tissue, while their systemic effects include fever, activation of the acute phase 
response and an increase of ACTH release from the pituitary gland. After surgery the 
major cytokines are interleukin-1, tumour necrosis factor-α and, in a secondary phase of 
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cytokine release, interleukin-6. The stimulation of ACTH leads to an increase in cortisol, 
which inhibits cytokine expression. The cortisol plasma concentration during major 
surgery in sufficient to depress the cytokine concentration by the negative feedback 
mechanism (Sheeran and Hall, 1997; Desborough, 2000). 
 
To summarise, the stress response results in a catabolic state causing an increase 
in blood glucose to mobilize energy in order to supply the damaged tissue (Tranquilli et 
al., 2007). This stress response and the accompanied physiological changes are meant to 
be acute and of limited duration.  However, in clinical settings the evoked stress response 
due to pain and trauma is argued to be unnecessary (Desborough, 2000) as it can lead to 
weight loss and muscle wastage as well as decreased immunity due to high plasma 
cortisol levels (Tranquilli et al., 2007). This stress response has been shown to increase 
mortality and morbidity in the clinical setting (Morrison et al., 2003).   
 
Hyperglycaemia produced by multiple hormonal interactions has been related to a 
higher mortality rate in critical ill patients after major surgeries (Egi et al., 2009). It is 
controversial if the hyperglycaemia is only a reflection of the severity of the illness or if it 
may cause harm on its own. The potential underlying mechanisms of hyperglycaemia-
induced mortality include promotion of sepsis, delayed wound healing and 
neuromyopathy (Kavanagh and McCowen, 2010).  
 
Moreover, excessive trauma and stress can cause widespread release of 
endogenous mediators such as cytokines that can subsequently result in the systemic 
inflammatory response syndrome, multiple organ failure and death (Silverstein, 2009). 
 
With analgesic and anaesthetic agents the stress response related to surgery or 
medical conditions can be controlled (Weissmann, 1990; Desborough, 2000). 
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2.2 Pain management 
Analgesic drugs can be divided into non-steroidal anti-inflammatory drugs (NSAIDs), α2-
adrenoreceptor agonists, opioids, local anaesthetics and others (Gaynor and Muir, 2009). 
These drugs act on different steps along the pain pathway.  
 
Monotherapy with only one agent is often not sufficient to achieve adequate 
analgesia in clinical settings; therefore, multimodal pain therapy has become the standard 
practice in human and veterinary medicine. Multimodal analgesia consists of the 
administration of more than one analgesic drug that acts at different levels on the pain 
pathway (Hellyer, 2004). An advantage of this multimodal therapy is that pain is better 
controlled because of additive or synergistic analgesic effects of the drugs. Another 
advantage is that lower doses of each drug are required, thereby reducing or even 
eliminating the potential adverse effects (Tranquilli et al., 2007; Lamont, 2008). The 
choice of drugs should be based on the mechanisms responsible for the pain pathogenesis 
(Woolf, 2000). Systemically administered drugs and regional anaesthetic techniques with 
local anaesthetics are often combined.  
 
2.2.1 Epidural analgesia 
A commonly used regional analgesic technique in veterinary medicine is the epidural 
administration of drugs (Bonath et al., 1984; Valverde, 2008). Epidural analgesia using 
local anaesthetics has been used in veterinary medicine since the 1950s. After the 
development of safer general anaesthetic agents epidural techniques were displaced, but 
with the discovery of the opioid action on the spinal cord in the 1980s (Yaksh and 
Noueihed, 1985), there was a re-emergence of epidural techniques as analgesic effects 
could be achieved using opioids without the side effects of motor paralysis due to 
administration of local anaesthetics (Valverde, 2008). Epidural techniques are now 
widely used for intra- and postoperative pain control and new drugs are being 
investigated (Hansen, 2001).  
 
Epidural administration of drugs reduces the need for systemic analgesic drugs 
(Torske and Dyson, 2000; Jones, 2008) and thereby reduces the development of systemic 
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adverse effects. The analgesia achieved by an epidural injection has been proven to have 
a faster onset of action, a higher potency and a longer duration compared to the systemic 
administration of the same drug (Bonath, 1986). By inhibiting the pain-pathway at the 
level of the spinal cord, central sensitisation can be avoided and the stress response is 
markedly decreased (Woolf, 2011). Furthermore, epidural analgesia leads to a better 
postoperative outcome (Grass, 2000; Rodgers et al., 2000; Jones, 2008).  
 
Before performing an epidural injection the patient should be carefully selected. 
Contraindications for epidural injections include septicaemia, coagulation disorders, 
trauma or infection in the area of injection and deformity of the anatomy (Hansen, 2001; 
Valverde, 2008) 
 
Epidural injections are commonly performed in the lumbosacral intervertebral 
space in small animals as it provides the largest access to the spinal canal (Jones, 2001). 
The dorsal intervertebral space in medium size dogs is approximately 2-4 mm. To insert a 
spinal needle in the epidural space the following anatomic structures need to be pierced: 
the skin, the subcutaneous fascia, the interspinous ligament and the prominent 
interarcuate ligament or ligamentum flavum. The meninges of the spinal cord from 
outermost to innermost are the dura mater, the arachnoidea and the pia mater. The dura 
mater is divided into an external and internal laminae. The external lamina is represented 
by the periosteum of the vertebral canal and only the internal lamina surrounds the spinal 
cord. The epidural injection is performed between the two laminae, which actually 
represents the intradural space. The epidural space is filled with fat to prevent the spinal 
cord from injury. The next meningx surrounding the spinal cord is the arachnoidea, which 
contains the cerebrospinal fluid (CSF). The arachnoid mater is named after its spider web 
appearance provided by trabeculae and fibrous tissue, which are in close contact with the 
pia mater. Injection of drugs into the fluid filled subarachnoid space is known as 
subarachnoid, spinal or intrathecal injection. The meningx closest to the spinal cord is the 
pia mater, which contains blood vessels to supply the spinal cord with nutrition and 
oxygen (Valverde, 2008).B 
 
In foetuses, the spinal cord extends as far as the sacrum. During growth, it shrinks 
within the vertebral canal as the growth of the vertebrae is faster than the spinal cord 
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growth. In large breed dogs the spinal cord terminates as the filium terminale at the fifth 
lumbar vertebra and in small breeds it ends at the level of the lumbosacral point. This 
anatomic feature makes it more likely to accidentally perform an intrathecal injection in 
smaller dog breeds and in paediatrics (Valverde, 2008). The subarachnoid space and the 
sac of the dura mater extend around 2 cm beyond the filium terminale. The sacral and 
caudal spinal roots form the cauda equina.  
 
 
 
The needle size should be chosen depending on the size of the dog. A 2.5 cm, 22 
Gauge (G) needle is recommended for small dogs, a 3.8 cm, 20 G needle for medium 
dogs and a 7.5 cm, 18 G needle for large dogs (Valverde, 2008).  
 
The epidural injection should be performed in sedated or anaesthetised animals to 
ensure correct needle placement by avoiding movement of the patient (Torske and Dyson, 
2000).  
 
Positioning of the animal in sternal recumbency is recommended as it is easier to 
insert the needle in the midline compared to a dog placed in lateral recumbency (Jones, 
2008). The hind limbs can be pulled forward to maximise the intervertebral space. 
Rotation of the patient in right or left lateral recumbency or in dorsal recumbency can be 
performed to allow increased spread of the drug over the desired vertebral bodies. For 
lumbosacral epidural injection, the anatomical landmarks include the external angles of 
the iliac crests (tuber coxae), the dorsal spinous process of the 7th lumbar vertebra and the 
sacrum. The area is prepared using a sterile technique and the needle is inserted in a 
straight angle through the skin (Jones, 2008). When the ligamentum flavum is pierced an 
increased resistance can be felt and is described as a “pop”. Correct placement in the 
epidural space is tested by injecting a small amount of air, sterile water or saline solution 
with lack of resistance. Other methods to ensure correct placement include the “hanging 
drop” technique, the measurement of force waves from the epidural space, the use of 
electrical stimulation (Valverde, 2008) and the injection of a small amount of radiological 
contrast (epidurogram) (Bartynski et al., 2005). In the study by Troncy et al. in 2002, 
epidural injection failure occurred in 7% of dogs undergoing surgery. The epidural 
Literature review  
26 
 
injections were performed in 242 anaesthetised dogs and a failure was considered as an 
inability to decrease the requirement of inhalant agent, which occurred in 17 dogs 
(Troncy et al., 2002). If cerebrospinal fluid is obtained the needle was inserted too far 
into the subarachnoid space. The spinal needle should be withdrawn to position it in the 
epidural space or, alternatively, the drug may be injected intrathecally but the injected 
dose should be reduced (Valverde, 2008). Torske et al. recommended a general drug 
reduction of 40% to 60% when drugs are injected intrathecally (Torske and Dyson, 
2000).  
 
Another technique performed in humans is an epidural in combination with an 
intrathecal injection. An epidural catheter is placed to ensure a prolonged block and 
intrathecal injection is performed with a low dose to obtain a rapid onset of action. This 
technique has been successful performed in a dog by Bonath et al. in 1984 (Bonath et al., 
1984) and Novello and Corletto in 2006 (Novello and Corletto, 2006).  
 
For a repeated or constant delivery of analgesic drugs, an epidural catheter may 
be placed (Hansen, 2001). A commercial kit is used containing a catheter and a Tuohy 
needle. The Tuohy needle has a round tip with a bevel to direct the catheter into the 
epidural space. The Tuohy needle is placed in the same manner as the spinal needle, but 
the “pop” is more pronounced as the needle is blunter. The stylet is removed and the 
epidural catheter threaded through the needle into the epidural space. If the needle is in 
the correct position the catheter can be inserted without any resistance. To secure the 
catheter it should be threaded far enough cranially so that movement of the skin will not 
retract the catheter. After this procedure the needle can be removed. To ensure adequate 
catheter placement radiographs may be obtained. The entry of the catheter through the 
skin should be protected with aseptic solutions and a bacterial filter is placed on the 
catheter (Hansen, 2001).  
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Figure 7: Lumbosacral epidural Tuohy needle placement in a dog. 
 
 
The cranial spread of the drug is largely dependent on the administered volume 
(Lee et al., 2004). Recommended volumes are 1 mL per 5 kg of body weight to extend up 
to the first lumbar vertebra, with a maximum volume of 6 mL as the epidural space is a 
fixed volume space and cannot contain excessive volumes (Torske and Dyson, 2000). 
Other authors recommend 0.3–0.5 mL per 10 cm from the occiput to the seventh lumbar 
vertebrae (Westhues and Fritsch, 1960). 
 
Local anaesthetic drugs are widely used in veterinary medicine (Tranquilli, et al., 
2007). They block the sodium-selective voltage-dependent ion channel in nerve fibres. As 
result the sodium influx in the afferent nerve fibres is decreased and depolarisation of the 
cell membrane becomes less likely (Mazoit, 2012). After the epidural injection, the local 
anaesthetic will diffuse into the intervertebral area and act on the distal part of the dorsal 
nerve roots. The drug will also spread from the intradural space through the arachnoidea 
into the subarachnoid space where it acts on the nerve roots. A direct action on the spinal 
cord is also suspected. The action of local anaesthetics extends to all nerves entering and 
leaving the spinal cord resulting in motor, sensory and autonomic blockade of nerve 
transmission (Torske and Dyson, 2000; Kokki, 2012). The onset of action depends on the 
diameter of the nerve fibre, with sympathetic blockade first, followed by sensory and 
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finally motor nerves. Therefore, local anaesthetics are likely to lead to motor paralysis, 
which results in ataxia and pelvic-limb weakness. Excessive cranial spread of the local 
anaesthetic into the thoracic vertebrae will result in sympathetic block with hypotension 
and decreased cardiac output (Valverde, 2008).  
 
Another group of drugs used for epidural analgesia are the opioids. Opioids 
gained attention and popularity as epidural or intrathecally administered drugs after the 
landmark study in 1976 by Yaksh et al. (Yaksh and Rudy, 1976).  
 
Opioids can be classified into opioid agonists, opioid agonist-antagonists and 
opioid antagonists. Opioid receptors are classified as μ, κ and δ receptors. The μ receptors 
are further subdivided into μ1, μ2 and μ3 receptors (Stoelting and Hillier, 2005). The μ1 
receptors mediate analgesia and euphoria and can lead to urinary retention, whereas the μ2 
receptors mediate analgesia and cause respiratory depression, bradycardia and physical 
dependence (Stoelting and Hillier, 2005). The μ3 receptors are located in peripheral 
nerves and lead to hyperpolarisation due to inflammation (Gaynor and Muir, 2009). The κ 
receptors are known to cause sedation, analgesia and dysphoria, and cause less physical 
dependence (Stoelting and Hillier, 2005). Lastly, the δ receptors modulate μ receptor 
activity (Gaynor and Muir, 2009). 
 
Opioid receptors are found in the periphery and in the CNS. They are widely 
distributed in pre- and postsynaptic neurons in the spinal cord, thalamus and cortex and 
are also part of the descending pain-pathways like the periaqueductal grey matter, nucleus 
raphe magnus and medulla (Inturrisi, 2002). All classes of opioid receptors are G-protein 
coupled and mediate inhibition of the adenylate-cyclase. They decrease presynaptic 
excitatory neurotransmitter release and inhibit postsynaptic conduction by 
hyperpolarising the cells. On presynaptic nerve terminals, they decrease calcium influx, 
which results in less substance-P release (Stoelting and Hillier, 2005). This effect is 
mainly seen on C-fibres and to a lesser extent and depending on the dose, on Aδ-fibres 
(Valverde, 2008). In postsynaptic neurons, they increase potassium efflux resulting in 
hyperpolarisation of the cells. In addition, they inhibit GABAergic inhibition action on 
inhibitory pain neurons in the central nervous system (Inturrisi, 2002). Another suspected 
site of action of opioids is at the NMDA-receptor in the dorsal horn of the spinal cord, 
enhancing the effects of NMDA-antagonists (Inturrisi, 2002). As a result, opioids lead to 
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a reduced neuronal action, which results in analgesia and/or sedation (Stoelting and 
Hillier, 2005). 
 
The main site of action of epidurally administered opioids is the dorsal horn of 
the spinal cord. After epidural injection, the drug binds to fat in the epidural space and 
penetrates the meninges. The arachnoid mater is the primary barrier for the administered 
drug. The possibility to penetrate this barrier is influenced by the lipid solubility. Opioids 
with a high lipid solubility such as fentanyl cross the arachnoid mater rapidly, which 
results in a fast onset of action and a short duration due to a high systemic absorption. 
Less lipid soluble drugs like morphine have been shown to have a slow onset and a long 
duration of effect, which makes this opioid the preferred one for epidural techniques in 
animals. Another pharmacokinetic factor affecting opioid effect is the epidural blood 
flow. An increased blood flow leads to an increase clearance from the epidural space and 
a higher systemic absorption rate. Sympathetic and motor blocks do not occur due to 
opioid administration (Valverde, 2008). 
 
When morphine is administered at a dose of 0.1 mg kg-1 epidurally to animals the 
onset time is 20–60 min (Jones, 2008; Valverde, 2008) and the analgesic duration of 
action varies from 10 to 24 hours (Torske and Dyson, 2000; Troncy et al., 2002; 
Valverde, 2008; Jones, 2008). This contrast with the systemic administration of 
morphine, which results in an analgesic effect lasting between 4 and 6 hours. Therefore, 
the epidural administration provides a much longer analgesic duration (Inturrisi, 2002). 
The rostral spread of morphine is extensive as there is a slow clearance from the CSF 
(Valverde, 2008). 
 
Side effects due to epidural opioid administration are dose dependent; therefore, 
side effects are more likely to occur when lipohilic opioids are administered as their 
systemic absorption and plasma levels are higher (Valverde, 2008). Complication rate due 
to epidural morphine administration is described at 0.75% in dogs and cats (Torske and 
Dyson, 2000). With regards to the cardiovascular system, epidural fentanyl and 
oxymorphone showed a dose dependent decrease in heart rate, a decrease in blood force 
and an increase in arterial carbon dioxide tension, whereby dogs treated with epidural 
morphine had better blood forces and cardiac output compared with the control group 
(Troncy et al., 2002). Respiratory depression is potentially the most serious adverse side 
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effect of epidural opioids. It manifests as a decrease in respiration rate and an increase in 
arterial carbon dioxide tension in dogs receiving morphine (Troncy et al., 2002). Usually 
the respiratory depression is related to a wide rostral spread and is delayed in relation to 
the time of administration. Additionally, urinary retention is described as an adverse 
effect, which occurs more commonly in humans (Valverde, 2008). Other adverse effects 
reported in humans are nausea and vomiting due to action on the medullary 
chemoreceptor trigger zone in the brain (Inturrisi, 2002). 
 
Adverse effects due to epidural injections are rare and epidural techniques are 
relatively safe. In humans, post-dural puncture headaches are reported as well as 
neurological symptoms (Kokki, 2012). Mechanical injury, abscesses and spinal cord 
infection have been described (Remedios et al., 1996; Swalander et al., 2000). Accidental 
intravascular injection can lead to systemic toxicity (Mulroy et al., 1997). However, the 
side effects are reduced and the analgesic effect is improved with epidural administration 
compared with systemic drug administration (Valverde, 2008). 
 
2.3 Magnesium 
2.3.1 Magnesium physiology 
Magnesium is the fourth most common mineral salt present in the human body after 
phosphorus, calcium and potassium. Mg2+ is the second most common intracellular cation 
after potassium (Dubé and Granary, 2003). 
 
Approximately 99% of the body magnesium is stored inside the cells. Of this 
amount, 67% of magnesium is in the bones together with calcium and phosphorus, 20% is 
stored in muscle tissue and 11% is found in other soft tissues. Only 1% of the total body 
magnesium is located outside the cells in the extracellular space. The exchange between 
the extracellular and intracellular magnesium stores is difficult to study but it appears that 
there is only a very slow exchange between bone and muscle and the extracellular space. 
Soft tissue seems to be much more able to liberate magnesium to the extracellular pool. 
The 1% extracellular magnesium is presented in three forms. The ionized form (active 
form, 55%) (Mg2+), the protein-bound form (20–30%) and the anion complexed form 
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(bound to phosphates and citrate, 15–25%). It is suspected that there is a shift between the 
free ionized form and the complex form (DiBartola, 2006). 
 
 The maintenance of an adequate magnesium balance is complex and mainly 
controlled by intestinal absorption and renal excretion. It is closely linked to other 
electrolytes like sodium, potassium and calcium (Reinhart, 1990).  
 
 The absorption of magnesium takes place between the ileum and the colon. Two 
pathways for intestinal magnesium absorption are well known. One pathway is the 
passive paracellular route, through the tight junctions between epithelial cells. The forces 
for this movement are the transepithelial magnesium concentration gradient, the 
transepithelial voltage gradient formed by water and salt absorption and the permeability 
of the tight junction to magnesium. The transepithelial magnesium gradient is influenced 
by the gut intraluminal Mg2+ concentration and the total dietary intake of magnesium as 
well as the amount of magnesium that is chelated. A small positive intraluminal voltage 
created by net movement of salt and water results in transepithelial cation movement. 
Additionally, cation movement results in solvent drag created by sodium and water 
absorbtion. The permeability of the tight junction is created by numerous ion channels. A 
specific magnesium ion channel has not been conclusively identified (DiBartola, 2006). 
The second existing pathway in the gut is the active transcellular route. At the moment 
there are a lot of investigations in this field of study, which focus on the hypothesis that 
several magnesium transport proteins exist (Quamme and Rouffignac, 2000). Parathyroid 
hormone (PTH) has been identified to have a positive influence on the magnesium 
absorption in the gut (Hardwick et al., 1991). The primary factor of the percentage of 
magnesium absorbed by transcellular and paracellular mechanisms is the dietary 
concentration of magnesium. A high magnesium intake creates a large concentration 
gradient and most absorption occurs through the paracellular route. Conversely, a poor 
magnesium intake results in a less efficient paracellular absorption and active 
transcellular magnesium transport becomes more important for adequate magnesium 
balance (DiBartola, 2006). 
 
 Magnesium transport in the kidney is influenced by calcium and several 
hormones. It is likely that similar control mechanisms influence magnesium absorption in 
the gut. The kidney provides the most sensitive control for magnesium balance (Quamme 
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and Rouffignac, 2000). In the glomerulus, 80% of total serum magnesium is filtered. 
Approximately only a small fraction of 15% is reabsorbed within the proximal tubuli. The 
reabsorbtion is mainly via passive and unsaturable mechanisms through paracellular 
transport. A large amount of magnesium (60%) is reabsorbed in the cortical thick 
ascending loop of Henle. Paracellular pathways through tight junctions seem to be the 
most important mechanism. The principal force allowing magnesium transport is the 
electropositive luminal environment created by the movement of sodium and chloride 
from the lumen to the interstitial space. In addition, magnesium movement in the 
interstitial space occurs as a result of solvent drag through the tight junctions. This 
mechanism implies that a change in transepithelial voltage influence the permeability for 
magnesium and additionally increase the absorption of magnesium. An increase in salt 
movement from the lumen will elevate the transepithelial electrical potential and facilitate 
magnesium absorption. Calcitonin, PTH, glucagon, antidiuretic hormone, aldosterone and 
insulin are known to increase magnesium absorption. On the other hand, prostaglandins, 
hypocalcaemia, hyphosphataemia and acidosis can decrease magnesium absorption. The 
distal convoluted tubuli do not act as mass transporter of magnesium but constitute the 
site that determine the final amount of magnesium excretion. Reabsorbtion of magnesium 
in this area appears to be mainly through active transcellular routes (Quamme and 
Rouffignac, 2000). 
 
 Magnesium has a fundamental role in many cellular functions. It is involved as a 
co-factor in more than 300 enzymatic reactions related to energy metabolism and nucleic 
acid synthesis (Fawcett et al., 1999). Magnesium has modulatory effects on sodium and 
potassium currents by regulating the Na2+-K+-ATPase, thus mediating a membrane 
stabilising effect (Herroeder et al., 2011). Magnesium acts by regulating and controlling 
different ion channels and its calcium antagonistic effects are well studied. Magnesium 
regulates calcium channels in cell membranes and sarcoplasmic reticulum. These results 
in a direct competitive antagonistic action directed against calcium influx into cells and 
outflow of calcium from the sarcoplasmic reticulum (Dubé and Granary, 2003).  
 
 In muscles, magnesium and calcium and have opposite effects. 
Hypomagnesaemia results in contraction and hypocalcaemia induces relaxation. The 
mechanism behind this effect is that hypomagnesaemia causes a rapid passive release of 
calcium by the sarcoplasmic reticulum, which leads to contraction. Magnesium influences 
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the neuromuscular transmission by blocking the entry of calcium into presynaptic endings 
which leads to a decrease in acetylcholine release. The decrease in acetylcholine has been 
shown to increase the threshold for axonal excitation. In conclusion, hypermagnesaemia 
causes neuromuscular weakness while hypomagnesaemia induces neuromuscular 
hyperexcitability (Dubé and Granary, 2003).  
 
Magnesium is known to inhibit catecholamine release by blocking calcium 
channels thus preventing calcium influx into symphathetic nerve endings. This 
results in modulation of the sympathetic reaction to nociceptive stimuli and stress 
response (Shimosawa, 2004). 
 
In the spinal cord, Mg2+ is a natural non-competitive NMDA-receptor antagonist 
and leads to an increased activation threshold (Mayer et al., 1984). It has been shown to 
induce analgesia (Mayer et al., 1984; Woolf, 2000; McCartney et al., 2004; Soave et al., 
2009) and has neuroprotective effects (Simpson et al., 1994). 
 
The measurement of magnesium to diagnose magnesium deficits is difficult and 
controversial. At present there is no simple, rapid and accurate laboratory test available to 
assess the amount of total body magnesium (Swaminathan, 2003). The fact that only 1% 
of the body magnesium is extracellular and only 55% of this is in the ionized form 
presents a diagnostic challenge to detect deficits. There are two different methods to 
assess magnesium clinically: either Mg2+ or the total magnesium in various tissues, most 
commonly blood.  
 
 Total serum magnesium is the most commonly used method of assessing 
magnesium as it is easy to obtain serum samples from patients and the assay is easy to 
perform and widely available (DiBartola, 2003). Other tissues (red blood cells, white 
blood cells, muscle tissue) have been used to measure magnesium concentration. 
However, because of the complexity of the assays, these methods are not routinely used 
in clinical practice. 
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 Another method to assess magnesium deficit is to assess the renal magnesium 
handling by testing the renal retention of magnesium. This assay is based on the idea that 
renal retention of magnesium occurs during magnesium deficit. Consequently, this assay 
can not be used in patients with inadequate renal function. However, these assays are not 
widely used in veterinary practice (DiBartola, 2003). 
 
 Normal total serum magnesium concentration for humans ranges between 0.75–
0.95 mmol/l (Musso, 2009), 0.76–0.96 mmol/l (Fawcett et al., 1999), 0.7–1 mmol/l 
(Herroeder et al., 2011), and 0.7–1.1 mmol/l (Swaminathan, 2003). In dogs, the normal 
range is 0.6–1.2 mmol/l (Clinical Pathology Laboratory reference range, Department of 
Companion Animal Clinical Studies, University of Pretoria). 
 
 Magnesium disorders such as hypomagnesaemia can be found in hospitalised 
patients and it is common in critically ill patients. Hypomagnesaemia is often associated 
with other metabolic disorders, as for example, hypokalaemia and hypophosphatemia. 
There are several causes of hypomagnesaemia. Common causes include disorders of the 
two regulating organs: kidney and gut. This results in a lack of input, less absorption or 
excessive elimination. Some of these conditions are for example: malnutrition, 
malabsorption, inflammatory bowel disease, diarrhoea, pancreatitis, hypercalcaemia, 
hyperaldosteronism, diabetes mellitus and hypoparathyroidism (Dubé and Granary, 
2003). Hypomagnesaemia manifests typically as cardiac and/or neuromuscular disorders. 
Clinical symptoms of hypomagnesaemia include anorexia, nausea, vomiting, generalized 
weakness, convulsion, tetani and changes in the electrocardiogram (Dubé and Granary, 
2003; Herroeder et al., 2011).  
 
 Hypermagnesaemia is less frequent and occurs in patients with chronic renal 
failure and due to rhabdomyolysis, or iatrogenically after excessive use of antacids or 
laxatives containing magnesium-salts or treatments for hypomagnesaemia. Clinical 
symptoms can range from nausea, vomiting and somnolence to deep coma (Dubé and 
Granary, 2003). 
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2.3.2 Magnesium as a systemic analgesic 
Magnesium as a physiological NMDA-receptor antagonist is thought to have analgesic 
properties by inhibiting central pain transmission at the level of the spinal cord  as well as 
inhibiting and preventing central sensitisation caused by peripheral nociceptive 
stimulation of long duration (Mebazaa et al., 2011). 
 
 Different studies in humans and animals have been performed on the analgesic 
effect of intravenous (IV) magnesium administration. Most studies administered 
magnesium sulphate (MgSO4) whilst others used magnesium as laevulinate (Wilder-
Smith et al., 1997), gluconate (Steinlechner, 2006) or chloride (Felsby et al., 1996). Most 
commonly, a single magnesium IV bolus was administered followed by a constant rate 
infusion (CRI) during surgery or for a certain period. But also single doses have been 
tested (Schulz-Stübner et al., 2001; Tramèr and Glynn 2007). The majority of these 
studies focused on the effect of magnesium on the total analgesic consumption in the 
intraoperative and postoperative periods. Some studies evaluated the effect of magnesium 
on neuropathic pain (Brill et al., 2002) and one study compared magnesium with the 
NMDA-receptor antagonist ketamine (Felsby et al., 1996). 
 
The magnesium doses used in different studies are very wide. Described IV bolus 
doses range from 5 mg kg-1  to 50 mg kg-1  (Apan et al., 2004, Ryu et al., 2008), and 
doses for CRI range from 8 mg kg-1  h to 500 mg h in humans (Kara et al., 2002; Apan et 
al., 2004). In animals, different doses of magnesium have been used, from a single 
injection of 600 mg kg-1  subcutaneously in rats (Xiao and Bennett, 1994), to a 50 mg kg-1  
bolus followed by a 15 mg kg-1  h CRI (Rioja et al., 2012) and a 50 mg kg-1 bolus 
followed by a 12 mg kg1 h CRI (Anagnostou et al., 2008). 
 
When magnesium was administered in humans during soft tissue surgery, such as 
hysterectomy or cardiac surgery, the opioid requirements decreased in the majority of 
studies (Tramer et al., 1996; Schulz-Stübner et al., 2001; Kara et al., 2002; Unlügenç et 
al., 2003; Apan et al., 2004; Seyhan, 2006; Steinlechner, 2006; Mentes et al., 2008; Ryu 
et al., 2008; Gupta et al., 2011; Kiran et al., 2011; Lee et al., 2011; Olgun et al., 2012), 
while it did not have any effect in other studies (Wilder-Smith et al., 1997; Zarauza et al., 
2000; Ko et al., 2001; Bhatia et al., 2004; Paech et al., 2006; Tramèr and Glynn, 2007; 
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Sullivan et al., 2012). When magnesium was administered in humans undergoing 
orthopaedic surgery, the opioid consumption decreased (Koinig et al., 1998; Telci et al., 
2002; Levaux et al., 2003; Hwang et al. 2009; Kogler, 2009). Furthermore, the 
administration of magnesium resulted in less postoperative discomfort and better quality 
of sleep (Tramer et al., 1996; Bhatia et al., 2004) and a lower incidence of postoperative 
shivering (Ryu et al., 2008).  
 
A study compared ketamine with magnesium chloride in humans suffering from 
peripheral neuropathic pain (Felsby et al., 1996). Ketamine or magnesium was 
administered by a bolus infusion followed by a CRI and pain was assessed using pain 
scales as well as mechanical and thermal threshold testing. Ketamine infusion, but not 
magnesium, reduced spontaneous pain and allodynia significantly. Mechanical and 
thermal thresholds were unchanged by both administered drugs. 
 
In a systematic review of 14 human randomized clinical trials, it was concluded 
that there was no effect of systemic administration of magensium on post-operative pain 
intensity and analgesic requirements (Lysakowski et al., 2007). 
 
In studies in rats, magnesium reduced allodynia (Xiao and Bennett, 1994). When 
magnesium was administered to dogs undergoing ovariohysterectomy it did not affect the 
analgesic consumption (Rioja et al., 2012). 
 
Possible reasons for the different results found in the previously mentioned 
studies include different dosages (Lysakowski et al., 2007), single bolus administration 
(Tramèr and Glynn, 2007), small number of patients (Rioja et al., 2012) and limited 
ability of magnesium to cross the blood brain barrier (Ko et al., 2001). 
 
2.3.3 Magnesium as a neuraxial analgesic 
Intravenous administration of magnesium is known to reduce intra- and postoperative 
analgesic requirements by acting as a physiological antagonist on the NMDA-receptor in 
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the dorsal spinal cord. Whether or not systemically administered magnesium
 
is able to 
penetrate the blood brain barrier remains unclear and an increase in serum magnesium 
concentration does not seem to increase the CSF concentration of magnesium (McCarthy 
et al., 1998; Ko et al., 2001; Sun et al., 2012). Therefore, the neuraxial administration of 
magnesium has been investigated in animal and human models of pain. 
 
The administration of high doses of magnesium
 
at the level of the spinal cord is 
proven to have no toxicity in rat models (Chanimov et al., 1997; Takano et al., 2000) as 
well as in dogs (Simpson et al., 1994) and cats (Tsai et al., 1994). However, dose 
dependant neurological dysfunction, neurotoxicity and no protective effect against 
ischaemic spinal cord injuries has been reported after intrathecal magnesium 
administration in rabbits (Saeki et al., 2004). 
 
 In rat models of pain, intrathecal magnesium enhanced spinal analgesia induced 
by opioids (Kroin et al., 2000) and delayed the development of opioid tolerance (Mc 
Carthy et al., 1998). Furthermore, intrathecal Magnesium induced motor block (Karasawa 
et al., 1998), sedation and sensory block (Bahar et al., 1996). Magnesium administered 
intrathecally reversed hyperalgesia induced by a magnesium deficiency (Begon et al., 
2001). High doses of magnesium
 
injected intrathecally showed analgesic effect using the 
formalin test in rats (Takano et al., 2000). Lower magnesium
 
doses and antinociception 
tested with other nociceptive tests failed to show any antinociceptive properties (Takano 
et al., 2000). The authors argued that this outcome could be due to the acute type of pain 
evoked by the different antinociceptive tests.  
 
The antinociceptive effect of epidurally administered magnesium
 
in different 
species has been investigated. Cross-over studies in goats (Bigham et al., 2009), horses 
(Bigham and Shafiei 2008) and cattle (Dehghani and Bigham, 2009b) have been 
performed using 1 ml of 10% magnesium
 
(100 mg) combined with 2% lidocaine in all 
studies. Time to onset of analgesia, duration of analgesia, standing time, cranial spread 
and vital parameters were assessed. The analgesic effect was measured recording the 
response to superficial and deep muscular pinpricks (Bigham et al., 2009) and pinpricks 
and force from haemostatic clamps (Bigham and Shafiei 2008; Dehghani and Bigham, 
2009b). In all species, the onset of analgesia was significantly prolonged in the lidocaine 
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combined with magnesium
 
treatment compared with the lidocaine treatement, but also the 
duration of analgesia was prolonged. Mild ataxia was observed in cattle and horses when 
only lidocaine was administered (Bigham and Shafiei 2008; Dehghani and Bigham, 
2009b). No difference in standing time was observed in goats (Bigham et al., 2009). The 
vital parameters did not differ significantly from baseline in both treatment groups 
(Bigham and Shafiei 2008; Bigham et al., 2009; Dehghani and Bigham, 2009b). In sheep, 
epidural administration of 50 mg of magnesium produced analgesia for approximately 29 
min and prolonged analgesia achieved by epidural ketamine (DeRossi et al., 2012). 
 
Different studies have been performed using intrathecal magnesium in clinical 
human trials. Most studies focused on the effect of magnesium on the onset, degree and 
duration of analgesia when administered in combination with opioids and/or local 
anaesthetics (Buvanendran et al., 2002; Ozalevli et al., 2005; Arcioni et al., 2007; El-
Kerdawy, 2008; Yousef and Amr 2010; Shukla et al., 2011; Nath et al., 2012) and the 
effect on postoperative opioid consumption (Bilir et al., 2007; Birbicer, et al., 2007;  El-
Kerdawy, 2008; Yousef and Amr 2010; Ouerghi et al., 2011). 
 
The first trial dealing with magnesium
 
intrathecally in humans included 26 
patients requesting analgesia for labour. Patients received fentanyl and magnesium
 
(50 
mg) intrathecally. The duration of analgesia was defined by the time the patient requested 
additional drugs for pain management. Duration of analgesia was significantly prolonged 
in the fentanyl plus magnesium treatment (75 min) compared with the fentanyl alone 
treatment (60 min). The authors argued that the prolonged duration might have limited 
clinical relevance, but that it might be due to the single bolus and the low dose of 
magnesium
 
administered (Buvanendran et al., 2002).  
 
Similar results were observed in Ozalevli et al’s study with patients undergoing 
lower extremity surgery (Ozalevli et al., 2005). Spinal anaesthesia was achieved by 
intrathecal administration of bupivacaine (10 mg), fentanyl (25 µg) and additional 50 mg 
magnesium. The main findings were that the onset of motor and sensory block were 
delayed and the duration of spinal anaesthesia was prolonged (median 173 min vs. 155 
min) in the group receiving additional magnesium
 .
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In another study in patients undergoing lower extremity orthopaedic surgery, a 50 
mg magnesium bolus followed by a CRI of 100 mg h magnesium was added to 
bupivacaine (10 mg) and fentanyl (25 µg) intrathecally (El-Kerdawy, 2008). The onset of 
spinal anaesthesia was significantly delayed in the group receiving magnesium, but the 
duration of analgesia was significantly longer. The overall postoperative fentanyl 
consumption was significantly lower in the magnesium group.  
 
In patients undergoing lower abdominal or lower limb procedure, 50 mg 
magnesium intrathecally delayed the onset of analgesia and prolonged analgesia achieved 
by bupivacaine (15 mg), but the analgesic duration was shorter compared to the group 
receiving additional dexmedetomidine (10 µg) (Shukla et al., 2011). 
 
Intrathecal magnesium
.
 (50 mg) in addition to fentanyl (25 µg) and morphine (3 
mg) in humans undergoing thoracotomy revealed a reduced postoperative analgesic 
requirement (Ouerghi et al., 2011). 
 
Magnesium (100 mg) administered intrathecally in combination with fentanyl 
(25 µg) and bupivacaine (12.5 mg) in patients undergoing hysterectomy produced a 
delayed onset of sensory and motor blocks and prolonged the duration of analgesia (Nath 
et al., 2012) . 
 
The postoperative fentanyl consumption was also significantly lower in a study 
including patients undergoing hip surgery (Bilir et al., 2007). One group (25 patients) 
received a continuous epidural infusion of fentanyl, whereas the other group received 
fentanyl combined with a 50 mg kg-1 magnesium bolus followed by a 100 mg kg-1 per day 
continuous infusion. Visual analogue scale scores were lower in the group receiving 
additional magnesium and the overall fentanyl consumption was significantly less.  
 
In another study, epidural magnesium
 
was added
 
(500 mg) to bupivacaine (25 
mg epidural and 10 mg intrathecal) and fentanyl (100 µg) in women undergoing 
caesarean section (Yousef and Amr, 2010). The magnesium group showed significantly 
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better muscle relaxation and delayed onset of postoperative pain, whilst postoperative 
analgesic requirements were significantly reduced. 
 
A study compared the different routes of neuraxial administration of magnesium 
(intrathecal, epidural, combined epidural and intrathecal) (Arcioni et al., 2007). 
Postoperative morphine consumption was assessed using patient controlled analgesia. 
Morphine consumption during 36 hours post-surgery was 38% lower in patients receiving 
magnesium epidurally, 49% lower in patients receiving magnesium intrathecally and 69% 
lower in patients administered a combined intrathecal and epidural injection of 
magnesium. 
 
However, epidural administration of 50 mg magnesium in combination with 
ropivacaine showed no effect on postoperative pain and analgesia requirement in 
paediatric patients undergoing lower abdominal or penoscrotal surgery (Birbicer, et al., 
2007). 
 
No difference in incidence of undesirable effects like bradycardia, hypotension or 
sedation in comparison to the control treatment was reported (Ozalevli et al., 2005; 
Ouerghi et al., 2011) 
 
To the author’s knowledge no studies of neuraxial magnesium
 
administration 
have been performed in dogs to date.  
 
2.4 Types of threshold testing 
Assessing pain in animals in an objective way presents a challenge in clinical, as well as 
in research settings. Different types of pain scales based on behavioural changes have 
been developed. Also the use of physiological parameters to assess pain has been 
investigated (Hansen 2003). Another method to assess pain is by using algometry, also 
called nociceptive threshold testing (Love et al., 2011). However, at present there is no 
established “gold standard” to assess pain as all the methods have limitations (Gaynor 
and Muir, 2009). 
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To investigate analgesic effects of drugs and to evaluate hyperalgesia, different 
nociceptive testing techniques have been used. The principle behind nociceptive testing is 
to apply a quantified nociceptive stimulus to a body part until a behavioural or reflex 
response is noticed, which indicates the pain threshold. The behavioural or reflex 
response is defined as the “end-point” and terminates the application of the nociceptive 
stimulus. The ideal analgesiometer was described by Beecher and is characterized by 
repeatability and a good reliability. In addition, it should be easy to apply and the end-
point should be easy to detect. The applied stimulus should be quantifiable, reproducible 
and non-invasive, causing no tissue damage and should be associated with perceived 
pain; furthermore, it should show a dose-response relationship (Beecher, 1957). 
 
There are several limitations to nociceptice algometry. The determination of the 
end-point can be challenging as it is dependent on the species and individual variability 
(Love, 2001). Furthermore, an experimenter bias is possible as the experimenter has to 
judge whether there was a response to the applied stimulus or not (Bove, 2006). Also the 
significance of the chosen end-point is important as a reflex response indicates a less 
complex conscious perception of pain than a more complex response (Bove, 2006). 
 
Nociceptive stimuli can be evoked by applying thermal, electrical, chemical and 
mechanical stimulation (Love, 2001). 
 
Thermal threshold testing, is commonly used in laboratory animals (Le Bars et 
al., 2001; Zhang et al., 2013) and domestic animals (Love, 2001; Pypendop et al., 2008).  
 
By using thermal nociceptive stimuli Aδ-fibres mechano-heat nociceptors and 
polymodal C-fibers are activated (Zhu and Lu, 2010). Other studies have demonstrated 
that the activation of the nociceptive fibres is dependent on the speed at which the 
temperature is increased. A rapid rate of heating activates Aδ-fibres whereas slow rate of 
heating activates polymodal C-fibres (Yeomans and Proudfit, 1996). 
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Commonly used thermal tests in laboratory animals are the “tail-flick” reflex 
response test, the “hot-plate” test (Beecher, 1957), the “tail-immersion” test (Luttinger, 
1985) and the “hind-paw thermal withdrawal” test (Dirig et al., 1997). These tests usually 
record the latency to a response following application of a constant temperature (Love, 
2001). In horses, a source of radiant heat (lamp) has been used for thermal testing with 
the end-point being latency period to hoof withdrawal or skin twitches (Carregaro et al., 
2007). An increase in time until a response occurs has been interpreted as an 
antinociceptive effect of tested drugs. One limitation of these methods is the inaccuracy 
associated with timing. If the time between exposure to the heat source and the response 
is short, this factor becomes more significant (Love, 2001). Animals may learn to avoid 
the nociceptive stimulus. Up to 50% of the horses showed avoidance towards the heat-
lamp before the stimulus was applied (Kamerling et al., 1985). Introducing a “sham test” 
in the study protocol by exposing the horses regularly to a non-heat producing lamp is 
suitable to eliminate the learning effect (Kamerling et al., 1985). An advantage of using 
radiant heat is that there is no contact between the skin and the heat source; therefore, 
there is no sensation of touch or force, which could evoke a reflex response (Beecher, 
1957). 
 
Another method of thermal threshold testing is using the thermode based system. 
A probe containing a heating element and a temperature sensor is held against a clipped 
area of skin. The contact of the probe with the skin can be regulated and modified by 
using a blood force cuff. The heating element heats at a constant rate until a change in 
behaviour is noticed. The behavioural change varies according to the species being tested. 
It can be a skin twitch or turn of the head in horses (Love, 2001) or jumping, turning the 
head, flicking the tail or licking and biting the probe in cats (Pypendop et al., 2008). The 
temperature at which the animal responds is referred to as the thermal threshold. In order 
to avoid tissue damage, should an animal not respond, a cut-out temperature has been set. 
In horses, different heating rates have been investigated. The slower the rate the more 
clear the end-point and the more consistent the threshold temperature (Love, 2001). These 
thermal threshold testing systems are criticised as they are in contact with the skin and 
can thereby evoke mechanical stimulation (Le Bars et al., 2001). 
 
Electrical stimuli are superior to other type of stimuli as they are quantifiable, 
non-invasive and reproducible, but this kind of stimulus also has disadvantages as it is not 
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a natural type of stimulus and activates all kinds of afferent fibres, from selective 
nociceptor Aδ and C-fibres up to large diameter non-nociceptive fibres. Furthermore, the 
impedance of the stimulated tissue can vary and makes it necessary to monitor the given 
current as well as the voltage required to generate the current (Le Bars et al., 2001). 
 
Tests using chemical stimuli differ from tests using other stimuli as chemical 
stimuli change progressively over time, are of longer duration and inescapable. They are 
known to be the closest experimental models to clinical pain. Usually a chemical agent is 
injected intradermally or intraperitoneally. Injections at other regions are less common. 
The injection of formalin is the most widely performed, but hypertonic saline, capsaicin 
and other substances have also been used. Pain response is dependent on the dose and 
concentration of the injected agent. The behavioural response (licking, biting, rest and 
protection of the injected limb) can be assessed and scored. Formalin causes a biphasic 
behavioural response in rats and mice. The first phase results from a direct activation of 
the nociceptors and the second response is due to inflammatory pain. Therefore, chemical 
stimuli can be used to evaluate analgesic effects of both opioids and NSAIDs. Opioids 
have been shown to suppress both phases of the pain response while NSAIDs only block 
the second phase (Le Bars et al., 2001).  
2.4.1 Mechanical threshold testing 
Mechanical threshold testing is mostly performed applying gradually increasing force 
over a given area of the skin until a behavioural end-point is reached. The responses can 
vary from a simple spinal reflex-response to vocalisation and complex changes in 
behaviour (Love, 2001).  
 
 The main criticism of mechanical threshold testing is that the applied force may 
be difficult to measure with precision and that a repetition of the stimulus can lead to an 
increase in threshold of the assessed body part (Le Bars et al., 2001). Activated receptors 
include low-threshold mechanoreceptors as well as nociceptors; therefore, this type of 
stimulus has been criticised for being not specific. To avoid the activation of low-
threshold mechanoreceptors it is necessary to apply a relatively high force, which leads to 
a weak sensitivity for nociceptive detection and can cause tissue damage and 
inflammation (Le Bars et al., 2001).  
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Different devices for different species have been developed (Le Bars et al., 2001). 
The main group of devices are based on von Frey’s investigations in 1922, when he 
developed the first monofilament by attaching a mammalian hair to a handle. Semmes 
and Weinstein further developed a set of nylon monofilaments of different diameters 
fixed on a handle. The theory behind monofilaments is to apply the monofilamet of a 
given thickness to a surface until it bends. The force generated remains constant 
throughout the bending excursion and the force is dependent on the thickness of the 
monofilament. When no response is evoked the next thicker filament is chosen and 
applied until a response is evoked and the threshold is determined (Bove, 2006). 
 
Different configurations of the monofilaments have been investigated. The probe 
has been fixed to a controlled mechanical advancer, producing a controlled force as with 
the Dynamic Plantar Aesthesiometer (Modell 37450; Ugo Basile Srl, Italy). On the other 
hand, the electronic von Frey device contains a rigid tip, which is manually applied, and 
the maximum force in grams that elicits an end-point is electronically recorded. 
 
Figure 8: Electronic Von Frey device, monitor and handle with rigid tip. 
 
 
 The main limitations of the mechanical threshold methods have been discussed 
by Bove et al. (Bove, 2006). Bending of the filament results in a change of the tip surface 
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and results in an edge being applied to the skin. The sharpness and area of the filament tip 
is dependent on the bending degree and increases with strength of the surface to which it 
is applied. This leads to an unpredictable force generation, dependent on tip geometry and 
strength of tissue to which it is applied (Bove, 2006). Some mechanical threshold devices, 
like the electrical von Frey device (Electronic von Frey, Model 23931; IITC Life Science, 
California, USA) are using rigid tips. Therefore, limitations discussed for flexible tips do 
not apply for the rigid tips. Other studies report that filaments meant to produce the same 
force do not, depending on the manufacturer (Booth and Young, 2000), and that 
interfilament variation from the same manufacturer also occurs (McGill et al., 1998). 
Further discussed is an experimenter bias, as the experimenter decides which filament is 
used and which behavioural change is considered as the end-point (Bove, 2006). Another 
point of criticism is the different ways of reporting monofilament threshold testing. The 
application of the monofilaments varies from not reporting duration of application 
(KuKanich et al., 2005), applying the tip for only one second (Duque et al., 2004; 
Lindegaard et al., 2009) or for up to more than 10 sec (Bove, 2006). The recording of the 
force applied varies from grams (Redua et al., 2002; Lindegaard et al., 2009) to newtons 
(Lascelles et al., 1997) to pascals (Bove, 2006). The reported changes are expressed in 
percentage changes from baseline (Lascelles et al., 1997; KuKanich et al., 2005) and 
changes in grams from baseline converted to logarithm scales (Redua et al., 2002; Duque 
et al., 2004). Therefore, a comparison between different studies and findings is very 
difficult.  
 
Other limitation are that a learning behaviour may occur, as the animal may learn 
to avoid the nociceptive stimulus (Love, 2001). However, in a study using von Frey 
filaments in dogs the threshold values in the control group did not change significantly 
over time compared to baseline (KuKanich et al., 2005). Another study comparing 
mechanical thresholds in horses on non-incision and incision site found no changes in 
mechanical thresholds at the non-incision site, while changes were found at the incision 
site, which proved absence of a learning process (Redua et al., 2002).  
 
Furthermore, mechanical threshold testing may be affected by environmental or 
external factors (e.g. time of the day, visual stimuli, noise, which may cause distraction 
and increase the thresholds) and internal factors like behaviour (e.g. frightened animals or 
very active animals would respond earlier than calm and friendly animals) (Bove, 2006). 
Literature review  
46 
 
 
In summary, all types of nociceptive stimuli have their limitations, advantages 
and disadvantages as well as different patterns of fibre activation. Overall, there is no 
“Gold Standard” in threshold testing. 
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3 Objectives and Hypotheses 
3.1 Objectives 
3.1.1 Primary objectives 
• To study whether magnesium administered in the lumbosacral epidural space in dogs 
produces antinociceptive effects determined using von Frey mechanical thresholds. 
• To study the possible antinociceptive interaction between magnesium and morphine 
when administered in combination in the lumbosacral epidural space in dogs 
determined using von Frey mechanical thresholds.  
 
3.1.2 Secondary objectives 
• To study the onset and duration of the antinociceptive effects produced by magnesium
 
alone or in combination with morphine when administered in the lumbosacral epidural 
space in dogs. 
• To study whether magnesium administered alone or in combination with morphine in 
the lumbosacral epidural space in dogs produces motor deficits.  
 
 
3.2 Hypotheses 
3.2.1 Primary hypotheses 
• Magnesium administered in the lumbosacral epidural space in dogs will produce an 
antinociceptive effect detectable using von Frey mechanical thresholds.  
• The combined administration of magnesium
 
and morphine in the lumbosacral epidural 
space in dogs will produce a greater antinociceptive effect compared with the 
administration of each drug alone.  
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3.2.2 Secondary hypotheses 
• The onset of action of the antinociceptive effect of magnesium administered in the 
lumbosacral epidural space in dogs will be longer and the duration shorter than 
morphine alone or the combination of magnesium and morphine. 
• Administration of magnesium
 
alone or in combination with morphine in the 
lumbosacral epidural space in dogs will not produce any motor deficits. 
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4 Material and Methods 
4.1 Dogs 
A total of six healthy, adult, neutered research Beagle dogs (3 male, 3 female) were 
enrolled in the study. The weight and age of the dogs were 15.2 ± 1.5 kg and 4 ± 1 years, 
respectively. Dogs were determined to be healthy prior to enrolment based on a clinical 
examination and blood work including a complete blood count, total serum protein and 
creatinine concentrations. Also, the dogs’ total serum magnesium concentration were 
determined to exclude states of hypomagnesaemia, as so exclude interfere with the study 
aim. Additionally, a clinical examination was performed every morning before the dogs 
were anaesthetized. Dogs were housed in cages and had daily regular access to a free run, 
they were fed with commercial dog food and had access to fresh water ad libitum. The 
University of Pretoria Animal Use and Care Committee approved the study (V074-11).  
 
4.2 Study design 
This was an experimental, randomized, blinded, crossover study. Dogs received four 
treatments in a random order with a one week washout period between treatments. 
Epidural injections consisted of: 
• Treatment control (Co): sterile water (0.115 mL kg-1) (Sabax water for injection 10 
mL Adcock Ingram Critical Care, South Africa).  
• Treatment magnesium (Mg): MgSO4 50% alone (0.005 mL kg-1, 2.5 mg kg-1) (Sabax 
Magnesium sulphate 50%; Adcock Ingram, South Africa). 
• Treatment morphine (Mo): morphine alone (0.1 mg kg-1) (Morphine Sulphate-
Fresenius PF 10 mg mL-1; Fresenius Kabi for Bodene, South Africa). 
• Treatment magnesium and morphine (Mm): a combination of MgSO4 (0.005 mL kg-1) 
and morphine (0.1 mg kg-1).  
 
Sterile water was added to treatments Mg, Mo and Mm to obtain a total volume 
of 0.115 mL kg-1. The above-described solutions were always prepared by the same 
anaesthetist (BD), who was not involved in the antinociceptive evaluations.  
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4.2.1 Anaesthesia 
A clinical examination was performed on the dogs every week in the morning before each 
treatment. Food was withdrawn for a minimum of six hours prior to anaesthesia, which 
was performed in the morning of the day of the treatment. A 20 G catheter (Jelco® I.V. 
Catheter Radiopaque purple 20 G x 1.75''; Smiths Medical International, UK) was 
aseptically placed in the cephalic vein. Anaesthesia was induced in study dogs using 
propofol (Propofol 1% Fresenius; Fresenius Kabi South Africa, South Africa), 
administered intravenously to effect (ranging from 6–8 mg kg-1) until loss of 
consciousness, and the trachea was intubated with a cuffed polyvinyl chloride endotrachel 
tube (size 8). Anaesthesia was maintained with isoflurane (Isofor Inhalation Anaesthetic; 
Saffeline Pharmaceuticals, South Africa) in 100% oxygen via a circle circuit rebreathing 
system, with a fresh gas flow rate of 1 L min-1. Vital parameters were continuously 
monitored during anaesthesia using a multiparameter monitor (SurgiVet Tm; Smiths 
Medical PM, Wisconsins, USA) including: respiration rate, haemoglobin oxygen 
saturation, expired CO2, electrocardiogram and arterial blood forces, measured 
noninvasively with an oscillometer. Dogs received 4 mL kg-1 h-1 of Lactated Ringer’s 
solution (Sabax Ringer-Lactate [Hartmann's Solution]; Adcock Ingram, South Africa) 
intravenously during anaesthesia. Rectal temperature was also measured before 
anaesthesia and in recovery. Dogs recovered from anaesthesia in sternal recumbency and 
under continuous observation from the primary researcher. 
 
4.2.2 Epidural catheter placement and drug administration 
Anaesthetised dogs were placed in sternal recumbency. The lumbosacral area was clipped 
and aseptically prepared using chlorhexidine and 90% alcohol. An 18 G x 4.45 cm Tuohy 
needle was inserted in the lumbosacral epidural space with the bevel pointing cranially. A 
volume of 0.5 to 2.5 mL of sterile water was injected to verify placement by lack of 
resistance to injection of a small volume and corroborate correct epidural needle 
placement. A 20 G epidural catheter was then introduced through the needle into the 
epidural canal (Epidural Catheterization Set with Flex-Tip Plus® Catheter for Pedriatric 
Lumbar Placement; Arrow International Special Order Products, South Africa) (Figure 
9). The epidural catheter was advanced 2 to 4 cm into the epidural space. Corresponding 
drugs were immediately administered through the epidural catheter with the dog still 
under anaesthesia. The order of administration of the drugs was done in a consistent 
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manner and time of injection was recorded. After the end of the epidural injection the 
epidural catheter was removed and the dogs were allowed to recover from anaesthesia. 
Epidural catheter placement and injection were always performed by a single experienced 
anaesthetist (ER), who was blinded to the treatments. 
 
Figure 9: Epidural catheter set, top-left 18 G x 4.45 cm Tuohy needle, bottom-right 20 G 
catheter with injection port attached (Epidural Catheterization Set with Flex Tip Plus® 
Catheter for Pedriatric Lumbar Placement; Arrow International Special Order Products, 
South Africa). 
 
 
4.2.3 Antinociceptive threshold testing using the von Frey device 
Antinociceptive threshold testing was performed using a von Frey device (Electronic von 
Frey, Model 23931 [modified]; IITC Life Science, California, USA). The device 
consisted of a load cell, a handle, a monitor and a rigid tip. The plastic tip (4.5 cm in 
length, 0.5 cm diameter) was custom built and modified by filling it completely with an 
epoxy putty (Repair Metal power Epoxy; Pattex, Germany), to increase the rigidity 
(Figure 10).  
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Figure 10: Rigid von Frey device custom built plastic tip (right) and tip filled completely 
with an epoxy putty (left). 
 
The load cell is designed to measure an applied force of 1 g to 1000 g. 
Calibration was performed each day of the study prior to data collection. The monitor 
retrains the maximum force applied in grams before withdrawal occurred. The operator, 
always the same person (AB), was trained to increase the applied force in a slow constant 
manner until a nociceptive response occurred.  
 
The repeatability of von Frey measurements was assessed prior to 
commencement of the experimental evaluation of treatments (phase 1 of the study). Three 
investigators (AB, ER and BD) performed two sets of measurements on two separate 
days, with three measurements on each region on the six dogs. Tested areas included the 
carpal pad, lateral surface of the epicondylus lateralis of the humerus, thoracic wall at the 
intercostal spaces 6 or 7, lateral surface of the thigh and plantar metatarsus, on both sides. 
These areas were clipped bilaterally for consistency. The most consistent results were 
obtained at the carpal pad (Cp), thorax (Th) and metatarsus (Mt) and, therefore, these 
areas were selected for the study (Figure 11). 
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Figure 11: Regions evaluated with the Von Frey device: carpal pads, both sides of thorax 
and metatarsi. 
         
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Threshold testing was performed in a temperature-controlled room with minimal 
restraint and minimal distraction of the dogs. Dogs were allowed to stand or lie in lateral 
recumbency during the measurements. During the experimental (phase 2 of the study) 
evaluation, measurements were performed by a single investigator (AB) who was blinded 
to the administered treatment.  
 
During the experimental evaluation, threshold testing was always performed in 
the morning prior to anaesthesia and epidural injection, which was considered the 
baseline and at 30 minutes, 1, 2, 4, 6, 12, 18 and 24 hours after the epidural injection. 
Three consecutive measurements were obtained at each region and on the left and right 
side at each time point. The maximum force at which a response was noted (the von Frey 
threshold) was recorded by a second observer also blinded to treatment group. The 
Carpal Pad 
Thorax 
Metatarsus 
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measured von Frey threshold were expressed in grams and the three measurements 
averaged for statistical analysis.  
 
Briefly, the tip was applied on each region perpendicular to the body surface on 
clipped skin and force was applied in a consistently increasing manner until a nociceptive 
response was obtained. A nociceptive response was considered withdrawal of the limb 
(Cp and Mt), a skin twitch or turning of the head (Th). A withdrawal reflex obtained in 
response to touching with the tip was not recorded as a nociceptive response. A 
maximum cut off force of 600 g was set. The investigator was notified to stop if this force 
was reached and it was recorded as the von Frey threshold. 
 
The assessments of the antinociceptive thresholds on the Cp were always 
performed with the dogs standing. The antinociceptive thresholds measured at the Th and 
the Mt were obtained whilst the dog was standing or in lateral recumbency, depending on 
the dog’s preference (Figure 12). The measurements were obtained first at the Cp, 
followed by the Th and lastly at the Mt. The left and right sides were assessed in random 
orders.  
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Figure 12: Electrical von Frey device applied to the metatarsus of a Beagle in lateral 
recumbency. 
 
 
Tested regions were visually inspected weekly for possible signs of tissue damage 
caused by the applied force. 
 
4.2.4 Additional measurements 
Dogs’ behaviour during the threshold testing was assessed using a numerical descriptive 
scale, with 0 being frightened, shy and quiet; 1 being calm and cooperative and easy to 
work with; 2 being anxious, unsettled and restless, but still possible to work with; and 3 
being excited, non-cooperative and difficult to work with. 
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The level of sedation after recovery from anaesthesia was also scored using a 
numerical descriptive scale, with 0 being not sedated, 1 being mildly sedated, 2 being 
moderately sedated, and 3 being severely sedated 
 
Tail tone was assessed to evaluated motor effects of the treatments. The degree of 
tail tone was scored using a numerical descriptive scale, with 0 having a normal tail tone, 
1 having a mild decrease in tail tone, 2 having a moderate decrease in tail tone, and 3 
having no tail tone. 
 
Additionally, ataxia of the pelvic limb was assessed to evaluated motor effects of 
the treatments. Ataxia of the pelvic limbs was scored with the dog walking three meters 
in a straight line using a numeric descriptive scale, with 0 being no ataxia, 1 mild ataxia, 
2 moderate ataxia, and 3 severe ataxia. 
 
Additional measurements were always obtained by the same person (AB), who 
was unaware of the treatments. Sedation, tail tone and ataxia were evaluated immediately 
prior to the von Frey thresholds measurement and behaviour was assessed after threshold 
testing at each time point. 
 
Room temperature and humidity were recorded at each time point during data 
collection with a combined thermometer/hygrometer (HOBBO Data Logger-U14-001; 
Onset, Massachusetts, USA). 
 
4.3 Statistical analysis 
Data were assessed for normality through the plotting of histograms, calculation of 
descriptive statistics and the Anderson-Darling test for normality. Outcome variables 
violating the normality assumption were transformed using natural logarithms or ranks 
prior to statistical analysis. Repeatability was assessed by calculating the coefficient of 
variation (standard deviation divided by the mean) of the three repeated measurements 
and by performing a variance components analysis. A linear mixed model was used to 
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analyse the effect of treatment and time on the von Frey thresholds. Dog was included as 
a random effect in the model and behaviour, side, region and week were included as fixed 
effects. Week of the study was evaluated as a potential confounder or effect modifier in 
the evaluation of treatment effects. Multiple pairwise comparisons were adjusted using 
Bonferroni correction. A non-parametric Freidman test was used to compare the 
distance of the epidural catheter within the canal among treatment. Data were 
analyzed using commercially available software (SPSS version 17.0; SPSS Inc; Chicago, 
Ill. USA) and results interpreted at the 5% level of significance. 
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5 Results 
5.1 Dogs 
Data are expressed as mean ± SD unless otherwise specified. Haematology and clinical 
examination prior to the study revealed no abnormalities in any dog. The blood serum 
total magnesium concentration was 0.8 ± 0.1 mmol/L, which was within the normal range 
of the University of Pretoria clinical pathology laboratory (0.6–1.2 mmol/L). 
 
5.2 Anaesthesia, epidural catheter placement and drug 
administration  
Anaesthesia was induced using 6.6 ± 1.3 mg kg-1 of propofol and total anaesthesia time 
was 13.0 ± 4.3 min. All vital parameters monitored during anaesthesia were within 
normal limits and no complications occurred. 
 
 Lumbosacral epidural catheter placement could be performed in all dogs. The 
epidural catheter was advanced 2.68 ± 1.06 cm into the epidural canal. The epidural 
injection could be completed in all dogs without any complications. The volume of 
injected drugs was 1.73 ± 0.17 mL. Additionally, a total of 1.42 ± 0.51 mL of sterile 
water was added to the injected drugs. Therefore, the total epidural volume was 3.17 ± 
0.68 mL. 
 
Induction, maintenance and recovery from anaesthesia were uneventful in all dogs. 
 
No signs of inflammation or tissue damage at the insertion site of the epidural 
catheter were noticed during the study. 
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5.3 Antinocicpetive threshold testing using the von Frey 
device 
 
Testing with the von Frey device was well tolerated by all dogs. There was no evidence 
of tissue damage, injury or lameness at any time point due to the applied force of the von 
Frey mechanical threshold testing. 
5.3.1 Repeatability of the von Frey threshold 
During phase 1 of the study, data collected from the Cp, Th and Mt had the highest 
repeatability (data not shown) and were selected for the evaluation of treatment effects. 
The mean coefficients of variation (range) of the von Frey thresholds for the three regions 
for the investigator AB was 20.8% (3.2%-40.3%); 27% (13.6%–49.8%) and 18.9% 
(3.7%–42.4%) at the Cp, Th and Mt sides, respectively (Figure 13). The majority (74%) 
of variability in the von Frey mechanical thresholds was unexplained, but 18.4% was 
attributed to the operator, 3.4% to the dog, 3.3% to the region and 0.7% to the day. 
 
Figure 13: Coefficients of variation (%) (mean [minimum, maximum])  of the von Frey 
threshold for the investigator (AB), at the CP, Th, Mt and all regions combined. 
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5.3.2 Antinocicpetive effects of the treatments 
Mechanical von Frey threshold values are presented as the median (interquartile range) 
grams. 
 
During phase 2 of the study, there was a significant effect of treatment and time 
in all regions. Threshold values varied significantly by region (p<0.001). Threshold 
values for Th were the highest, followed by Mt and Cp (Table 1). Baseline thresholds at 
each region were similar throughout the study and did not significantly vary by week.  
 
Table 1: Overall mechanical threshold values in gram (median [interquartile range]) 
obtained with the von Frey device at the Cp, Th and Mt. 
Regions Median 
Cp 138 (118-165) 
Th 172 (140-214) 
Mt 162 (136-192) 
 
Treatment had a significant effect on the von Frey threshold values when 
combined over all regions (p<0.001). Overall threshold values for treatment Co were 
significantly lower compared with the three other treatments (p<0.001). Overall threshold 
values for treatment Mm were significantly lower compared with Mg (p=0.022). No 
differences in overall threshold values when combined over all regions were found 
between Mo and Mg treatments.  
 
Treatment also had a significant effect on the von Frey threshold values at the 
three independent regions, Cp (p<0.001), Mt (p<0.001) and Th (p<0.001). 
 
At the Cp, treatment Co had the lowest obtained threshold readings. Threshold 
values at the Cp obtained with treatment Co were significantly lower than with treatment 
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Mo (p=0.019) and treatment Mg (p<0.001), but they were not significantly different from 
treatment Mm (p=0.099) (Table 2).  
 
At the Th, treatment Co had the lowest obtained threshold readings. Threshold 
values at the Th obtained with treatment Co were significantly lower than with treatment 
Mo (p=0.014), treatment Mg (p<0.001) and treatment Mm (p=0.012) (Table 2).  
 
At the Mt, treatment Co had the lowest obtained threshold readings. Threshold 
values at the Mt obtained with treatment Co were significantly lower than with treatment 
Mo (p<0.001), treatment Mg (p<0.001) and treatment Mm (p=0.003) (Table 2).  
 
There were no significant differences in threshold values comparing Mo, Mg and 
Mm analysed for each region (Table 2). 
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5.3.3 Changes in the antinociceptive threshold over time for regions 
Time had a significant effect on the von Frey threshold values. Overall von Frey 
threshold values (when treatments and regions were combined) were significantly 
increased at 30 min, 2, 4, 6 and 12 hours after injection of the treatments compared with 
baseline values (p<0.001, p=0.002, p=0.001, p=0.01, p<0.001, respectively). The 
measurement obtained at 1 hour after treatment administration was increased compared to 
baseline, but it did not reach statistical significance (p=0.073) (Table 3).  
 
At the Cp, time significantly influenced the mechanical threshold values at the 
time point 30 min (p<0.001) after injection of the treatments (Table 3). 
 
At the Th, time did significantly influence the obtained mechanical thresholds 
values. The threshold values were significantly elevated compared to baseline at 30 min, 
1, 2, 4, 6 and 12 hours after injection of the treatments (p<0.001, p<0.001, p<0.001, 
p<0.001, p<0.001, p=0.002, respectively) (Table 3). 
 
At the Mt, time did significantly influence the obtained mechanical threshold 
values. The threshold values were significantly elevated compared to baseline at 30 min 
and 2 hours after injection of the treatments (p=0.007, p=0.003, respectively) (Table 3)
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5.3.4 Changes in the antinociceptive threshold over time for 
treatments 
Von Frey threshold values when regions were combined showed a significant effect of 
time for the different treatments (Table 4). 
 
The Co treatment had a significantly elevated threshold compared to baseline at 
30min, 2, 4 and 12 hours after injection of the treatments (Table 4).  
 
The Mg treatment had a significantly elevated threshold compared to baseline at 
30min after injection of the treatments (Table 4).  
 
The Mo treatment had a significantly elevated threshold compared to baseline at 
4 hours after injection of the treatments (Table 4).  
 
The Mm treatment had a significantly elevated threshold compared to baseline at 
2 hours after injection of the treatments (Table 4).  
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Figure 14 illustrates the actual mechanical threshold values over time obtained at 
the Cp for all four treatments separately. No statistical significance could be detected at 
any time point. 
 
Figure 14: Mean (SD) threshold values obtained at the Cp over time with the four 
treatments.  
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Figure 15 illustrates the predicted mechanical threshold values over time obtained 
at the Cp for all four treatments separately.  
 
Figure 15: Mean (SD) predicted threshold values obtained at the Cp over time with the 
four treatments.  
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Figure 16 illustrates the actual mechanical threshold values over time obtained at 
the Th for all four treatments separately. No statistical significance could be detected at 
any time point. 
 
Figure 16: Mean (SD) actual threshold values obtained at the Th over time with the four 
treatments.  
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Figure 17 illustrates the predicted mechanical threshold values over time obtained 
at the Th for all four treatments separately.  
 
Figure 17: Mean (SD) predicted threshold values obtained at the Th over time with the 
four treatments.  
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Figure 18 illustrates the actual mechanical threshold values over time obtained at 
the Mt for all four treatments separately. No statistical significance could be detected at 
any time point. 
 
Figure 18: Mean (SD) actual threshold values obtained at the Mt over time with the four 
treatments.  
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Figure 19 illustrates the predicted mechanical threshold values over time obtained 
at the Mt for all four treatments separately.  
 
Figure 19: Mean (SD) predicted threshold values obtained at the Mt over time with the 
four treatments.  
 
 
In summary, a trend for onset and duration of the antinociceptive effects of the 
different treatments could be illustrated, although no significant differences were found 
between time points for individual treatments, only when all treatments were combined. 
There was an increase in the threshold values 30 min after administration of all treatments 
in all regions. Threshold values seemed to increase again between 4-6 hours after drug 
administration. Return to baseline values seemed to occur 18 hours post-injection. 
Finally, a slight increase in threshold values seemed to take place 24 hours post-injection.    
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5.3.5 Changes in the antinociceptive thresholds over time in 
individual dogs for each treatment 
5.3.5.1 Changes in the antinociceptive threshold over time for treatment Co 
Figure 20: Threshold values obtained at the Cp over time for treatment Co.  
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Figure 21: Threshold values obtained at the Th over time for treatment Co. 
 
 
Figure 22: Threshold values obtained at the Mt over time for treatment Co. 
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5.3.5.2 Changes in the antinociceptive threshold over time for treatment Mo 
Figure 23: Threshold values obtained at the Cp over time for treatment Mo.  
 
 
Figure 24: Threshold values obtained at the Th over time for treatment Mo. 
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Figure 25: Threshold values obtained at the Mt over time for treatment Mo. 
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5.3.5.3 Changes in the antinociceptive threshold over time for treatment Mg 
Figure 26: Threshold values obtained at the Cp over time for treatment Mg. 
 
 
Figure 27: Threshold values obtained at the Th over time for treatment Mg. 
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Figure 28: Threshold values obtained at the Mt over time for treatment Mg. 
 
 
5.3.5.4 Changes in the antinociceptive threshold over time for treatment Mm 
Figure 29: Threshold values obtained at the Cp over time for treatment Mm. 
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Figure 30: Threshold values obtained at the Th over time for treatment Mm. 
 
 
Figure 31: Threshold values obtained at the Mt over time for treatment Mm. 
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5.3.6 Effect of side on the thresholds 
There was a significant effect of side on the mechanical threshold values (p<0.001) on all 
three regions (Table 5). 
 
Table 5: Median (range) mechanical threshold values obtained on the right and left sides 
in grams. * Significant difference compared to the right side (p<0.05). 
 Left Right 
Regions combined 157 (130, 193) * 154 (126, 189) 
Cp 141 (120, 171) * 135 (115, 159) 
Th 171 (140, 213) * 174 (139, 216) 
Mt 165 (136, 196) * 160 (133, 188) 
 
 
5.4 Additional measurements 
5.4.1 Sedation 
Thirty minutes after epidural injection, the majority of dogs were mildly (58%) to 
moderately (13%) (Figure 30) sedated. Sixty minutes after epidural injection, most dogs 
were non-sedated (67%) and 120 minutes after epidural injection, only two dogs (4%) 
still showed mild signs of sedation (both receiving Mo treatment).  
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Figure 32: Sedation score obtained 30, 60 and 120 minutes after epidural injection of the 
treatments; no sedation (0), mild sedation (1) and moderate sedation (2) 
 
 
5.4.2 Behaviour 
Behaviour score 1 was most commonly given (78%), followed by score 2 (15%) and 
score 3 (5%). Behaviour score 0 was given 5 times in only two dogs (3%) (Figure 31). 
 
Dogs with behaviour score 0 had significantly higher overall threshold values 
(166 [137,189]) compared to dogs with a behaviour score 2 (164 [133, 197]) (p = 0.045).  
 
At the Mt, dogs with a behaviour score 3 had significantly higher threshold 
values (185 [156, 215]) than dogs with a behaviour score 2 (172 [145, 197]) (p = 0.029). 
At the other regions, no significant differences in mechanical thresholds could be detected 
between the behaviour scores. 
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Figure 33: Illustration of behavior scores observed in dogs in %.  
 
 
5.4.3 Motor effects 
The tail tone scores were always 0 on all dogs at all time points with all treatments. 
 
The scores for ataxia were always 0 on all dogs at all time points with all 
treatments.  
 
5.4.4 Room temperature and humidity 
The median (range) room temperature was 24.9°C (26.8°C–21.4°C) and humidity was 
65% (79%–49%) throughout the study. 
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6 Discussion 
Lumbosacral epidural injections in dogs can be challenging and failures of epidural 
injection are reported to range from 7% (Troncy et al., 2002) to 12% (Heath, 1992). To 
avoid epidural injection failures and therefore, false negative results an epidural catheter 
was placed in all dogs before each treatment. Correct epidural catheter placement was 
assessed by lack of resistance to advancement of the catheter cranially and lack of 
resistance to injection of sterile water. A more accurate method to ensure correct epidural 
needle placement is the performance of a fluoroscopy and epidurogram (El-Khoury et al., 
1988; Bartynski et al., 2005). However, due to ethical consideration regarding the X-ray 
exposure these methods could not be performed in the dogs enrolled in the study. 
 
The used morphine dose of 0.1 mg kg-1 is the recommended dose for epidural 
administration in dogs by several authors (Tranquilli et al., 2007; Valverde, 2008). Side 
effects due to epidural morphine administration are rare including respiratory depression, 
urinary retention and pruritus at the injection site (Torske and Dyson, 2000). In this study 
no side effects could be observed.  
 
There are no previous studies investigating the antinociceptive effects of epidural 
magnesium administration in dogs in the literature. The doses of neuraxial magnesium 
described in the literature are very variable. In humans, a single dose of 50 mg of 
magnesium has been most commonly used intrathecally with no apparent adverse effects 
(Buvanendran et al., 2002; Ozalevli et al., 2005; Shukla et al., 2011). Epidurally, 500 mg 
bolus (Yousef and Amr, 2010) and 50 mg bolus with intrathecal CRI of 100 mg hour has 
been investigated (Bilir et al., 2007; El-Kerdawy, 2008). Epidural doses of 0.18 mg kg-1 
have been administered in horses (Bigham & Shafiei 2008), 0.21 mg kg-1 in cattle 
(Dehghani and Bigham, 2009a), and 2 mg kg-1 in goats (Bigham et al., 2009) in 
combination with local anaesthetics. A dose of 3 mg kg-1 of magnesium administered 
intrathecally to dogs did not cause any adverse effects and it seemed to possess 
neuroprotective effects (Simpson et al. 1994). However, neurotoxicity was observed after 
3 mg kg-1 intrathecal magnesium administration in rabbits (Saeki et al., 2004). Based on 
the lack of clinically recommended doses and the apparent safety of epidural magnesium, 
a relatively high dose of 2.5 mg kg-1 was used in the present study.  
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The antinociceptive effect of magnesium extended up to the thoracic limbs. The 
dispersion of a drug in the epidural space is dependent on the injected volume, the force 
within the epidural space (Torske and Dyson, 2000) and the lipid solubility of the drug, as 
these factors facilitate the absorption across the dura membrane and into the cerebrospinal 
fluid (Valverde, 2008). The total volume administered was approximately equivalent to a 
volume of 0.2 mL kg-1, which has been described to migrate up to the thoracolumbar area 
(Torske and Dyson, 2000; Valverde, 2008). The observed effect on the thoracic limbs has 
been previously described with lumbosacral epidural morphine (Valverde, 2008) and 
subsequently explained the absorption of the drug into the cerebrospinal fluid, which 
promoted its cranial migration (Valverde, 2008). 
 
The von Frey device was used to determine increase in antinociceptive 
mechanical thresholds following morphine and magnesium
 
epidural administration. The 
von Frey device is validated for antinociceptive threshold testing in dogs and various 
other species (Jensen and Yaksh, 1986; Redua et al., 2002; Vivancos et al., 2004; 
KuKanich et al., 2005). In this study, the rigidity of the tip was increased using an epoxy 
putty to avoid bending of the tip with application of high force as described in KuKanich 
et al.’s study in 2005 (KuKanich et al., 2005). Bending of the tip would lead to a change 
in the surface area being applied to the body, thereby producing an unpredictable change 
in the force applied (Bove, 2006). With this modification no bending occurred in any of 
the measurements, regardless of the force applied. The same tip was used throughout the 
whole study to avoid a source of possible variability (Booth and Young, 2000).  
 
The end-point of threshold testing was defined in a pilot study before 
commencement of the study and the principal investigator (AB) was trained to apply the 
force in a constant manner. Furthermore, to avoid possible observer bias (Bove, 2006), 
the principal investigator was blinded to the maximum reading obtained, which was 
recorded by a second person. 
 
The negative control, treatment Co, had overall the lowest thresholds at all 
regions and therefore, as expected, no detectable analgesic effects. There was no evidence 
of change in thresholds obtained for treatment Co overtime that could be attributed to 
tolerance, hyperaesthesia or learning behaviour.  
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The Mo treatment, used as a positive control, showed significantly higher 
thresholds compared to the negative control treatment Co. This effect could be observed 
at all three measured regions separately as well as in the overall analysis. The significant 
increase in threshold at the carpal pads indicates that the analgesic effect of morphine 
reached up to the front limbs as described in another study (Valverde et al., 1989). The 
analgesic effect of morphine is mainly due to its action on C-fibres in the dorsal horn of 
the spinal cord, on central pain perception as well as on descending pain pathways 
(Stoelting and Hillier, 2005) and only at high doses it also affects Aδ fibres (Djouhri and 
Lawson, 2004). The nociceptive stimulus elicited by the von Frey device is mechanical 
and causes activation of Aδ (high-threshold mechano-heat and mechano-cold 
nociceptors) and polymodal C-fibres (Djouhri and Lawson, 2004). The pain elicited by 
the von Frey device can be described as similar to naturally occurring pain (Le Bars et al., 
2001). The results of the present study show that the administered morphine did have an 
analgesic effect and that the von Frey device was sensitive enough to show this effect. 
 
As hypothesised, the magnesium treatment showed significantly higher 
thresholds compared with treatment Co. This analgesic effect was identified on all 
measured regions. This implies that epidural magnesium
 
mediated an analgesic effect that 
spread up to the front limbs. Interestingly, the thresholds obtained in magnesium 
treatment were numerically the highest of all groups, although this was not statistically 
significant. Similar results were found in the study by Bahr et al. in 1996 (Bahar et al., 
1996), where intrathecal magnesium also induced sensory block, although in this study 
they also showed motor block and sedation. The analgesic effect of magnesium
 
is thought 
to be due to its antagonistic action at the NMDA-receptor (Dubé and Granary, 2003). The 
NMDA-receptor is mainly activated by continuous nociceptive input from C-fibres and 
contributes to the development of central sensitisation (Bhatia et al., 2004). Other 
possible mechanisms for the antinociceptive effect of magnesium include inhibition of 
catecholamine release causing a decrease in neuronal activity (Shimosawa, 2004), 
inhibition of acetylcholine release or membrane stabilization (Herroeder et al., 2011). All 
these mechanisms are due to the calcium-antagonistic effects of magnesium (Fawcett et 
al., 1999). The obtained serum magnesium levels were all within normal limits (0.6-1.2 
mmol/L) and all dogs were healthy; hence a state of hypomagnesaemia in these dogs was 
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unlikely. Therefore, the antinociceptive effect of magnesium
 
was most likely due to its 
direct effect on the spinal cord and not due to the correction of a magnesium deficiency.  
 
Neuraxial administration of magnesium
 
(epidural and intrathecal) in combination 
with opioids and/or local anaesthetics provides a longer duration of analgesia 
(Buvanendran et al., 2002; Ozalevli et al., 2005; Yousef and Amr, 2010; Shukla et al., 
2011; Nath et al., 2012), a post-operative opioid sparing effect (Arcioni et al., 2007; 
Ouerghi et al., 2011; Khezri et al., 2012). A synergistic effect between magnesium
 
and 
opioids has been previously postulated (Tramer et al., 1996). This possible interaction 
was investigated in this study by administering both drugs in combination. Treatment 
Mm had significantly higher thresholds compared with treatment Co when all regions 
were analysed together and at the thorax and metatarsi. At the carpal pads, thresholds 
obtained were numerically higher than in treatment Co, but it did not reach statistical 
significance. It is possible that with a greater sample size an effect on the front limbs 
could have been also observed.  However, no enhancement of antinociception was 
observed when magnesium was combined with morphine since the thresholds were not 
significantly different from those obtained with morphine or magnesium administered 
alone. Therefore, no synergistic or additive effect could be demonstrated in this study. A 
possible explanation could be the limited sample size of six dogs. Another possibility is 
that the nociception elicited by the von Frey device is of different quality and intensity 
than pain elicited by surgeries (Ozalevli et al., 2005; El-Kerdawy, 2008; Yousef and 
Amr, 2010), and therefore, the synergistic effect of opioids in combination with 
magnesium seen in patients undergoing surgeries might be due to the difference in pain 
experience. Both opioids and magnesium
 
have an antagonistic action on calcium 
channels, preventing calcium influx into pre-synaptic cells leading to a decrease in 
excitatory transmitter release (Tranquilli et al., 2007; Fawcett et al., 1999). Therefore, a 
ceiling effect on the inhibition of the pre-synaptic calcium channels could have been 
reached when both drugs were administered together, which may have prevented an 
enhancement of the antinociceptive effect. Another possibility is that the dose of 
magnesium
 
was either too high or too low to observe a synergistic interaction with 
morphine. A dose-finding study would be necessary to establish this.   
 
An increase in mechanical thresholds was observed 30 min after drug 
administration with all treatments and decreased 1 hour after injection compared to 
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baseline. The measurement obtained 1 hour after injection showed no significant increase 
compared with baseline. During the first von Frey threshold testing 30 min post-injection 
most of the dogs were mildly to moderately sedated, whereas 1 hour post-injection less 
than half of the dogs showed signs of sedation. Therefore, the increase in threshold at 30 
min could have been due to sedation. A sedated dog is more likely to respond only to 
nociceptive stimuli of greater intensity and the reaction time might also be prolonged 
compared with a non-sedated dog (Beecher, 1957). However, in a study performed by 
KuKanich et al. in 2005 (KuKanich et al., 2005), a high dose of intravenous morphine 
was administered to dogs and the reported sedation lasted for 7-12 hours whereas 
antinociception, evaluated with the von Frey device, only lasted for 4 hours. Based on 
these results the authors suggested that von Frey mechanical thresholds were able to 
discriminate between antinociceptive effects and sedation. In our study, the observed 
sedation of the dogs was most likely due to residual anaesthesia from isoflurane (Lopez et 
al., 2009), which might be different from the sedation mediated by IV morphine. Another 
possible explanation for the increase in thresholds 30 min post-injection is the rapid 
initial systemic absorption of the injected drugs causing systemic rather than neuraxial 
analgesia, as has been shown following epidural morphine in dogs (Valverde et al., 
1992).  
 
An increase in thresholds was observed from 30 min to 12 hours, excluding 1 
hour, compared with baseline following administration of all treatments when all regions 
were pooled together. An onset and duration of the individual treatments could not be 
established.  
 
Interestingly the control group showed a significant increase in threshold over 
time compared to baseline when treatments were analysed separately. These observation 
remains unexplained. An increase of power might be necessary to detect differences in 
the pairwise comparisons for the individual treatments. A larger sample size would be 
necessary to detect onset and duration of each individual treatment. An onset of action for 
epidural morphine is reported to be 20-60 min (Jones, 2001; Valverde, 2008). In the 
literature magnesium is described to delay the onset of analgesia achieved with opioids 
and local anaesthetics (Ozalevli et al., 2005; El-Kerdawy, 2008). The duration of the 
analgesic action of epidural morphine in dogs reported in the literature varies from 10 to 
23 hours (Torske and Dyson, 2000), 12 to 24 hours (Valverde, 2008), 16 hours (Troncy et 
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al., 2002) and 16 to 24 hours (Jones, 2001). It was expected that magnesium would 
prolong the analgesic effect of morphine as previously described (Ozalevli et al., 2005;  
Shukla et al., 2011; Nath et al., 2012); however, this could not be determined with the 
methods used in this study. 
 
Little is known about onset of action of epidural magnesium. In a study 
performed in humans the onset of systemically administered magnesium
 
is approximately 
30 min (Brill et al., 2002). A delayed onset of analgesia is described in humans when 
magnesium is added to spinal anaesthesia (Ozalevli et al., 2005; El-Kerdawy, 2008) 
Epidural injection of magnesium
 
in combination with lidocaine in goats (Bigham et al., 
2009), horses (Yousef and Amr, 2010) and cattle (Dehghani and Bigham, 2009b) results 
in a rapid onset of analgesic action of a few minutes, which could be due to the rapid 
onset of action of lidocaine (Valverde, 2008). Interestingly, these studies report a delayed 
onset of a few minutes when magnesium is added compared to the administration of 
lidocaine alone.  
 
Little is known about the duration of antinociception of epidural magnesium
 
administered alone. In sheep epidural magnesium
 
produced an analgesic effect lasting 
approximately 29 minutes (DeRossi et al., 2012). When magnesium
 
is administered in 
combination with lidocaine, the duration of analgesia is reported to be approximately 3 
hours (Bigham et al., 2009; Dehghani and Bigham, 2009b; Yousef and Amr, 2010). In 
humans, intrathecal
 
magnesium
 
in combination with a local anaesthetic and an
 
opioid 
resulted in an analgesic effect of approximately 2 hours (Ozalevli et al., 2005).  
 
A potentiation of the analgesic effect of morphine with magnesium may be 
demonstrated by obtaining higher thresholds or by observing a prolonged duration of 
effect compared to each drug administered individually (Ozalevli et al., 2005; Shukla et 
al., 2011; Nath et al., 2012). An increase in the duration of the antinociceptive effect 
could not be demonstrated in this study. Possible explanations could be the limited 
sample size, the lack of clinical pain and/or the lack of sensitivity of the methods used.  
 
Interestingly, the thresholds obtained on the left side were significantly higher 
than on the right side in all regions. The position of the patient after an epidural injection 
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is known to influence the contact of the agent with the target tissue and therefore, 
influence the spread of the drug (Valverde, 2008). In the present study, the epidural 
injection was performed with the dogs in sternal recumbency and during recovery the 
dogs remained in sternal recumbency until they were able to stand and walk on their own. 
Also, during the von Frey testing, dogs remained in standing or sitting position. During 
threshold measurements at the thorax, some dogs were positioned in lateral recumbency; 
however, this was approximately 35 min after injection and the spread of epidurally 
administered drugs is believed to be complete after 5 minutes post-injection (Tranquilli et 
al., 2007). Therefore, it is unlikely that the change in position at this point in time might 
have influenced the spread of the drugs. Another possible explanation is the lateralization 
of the epidural catheter during its introduction into the epidural canal. The same person 
(ER) performed all the catheter placements and used the same technique. This 
investigator is right handed and this could have influenced the lateralization of the 
catheter towards the left side.   
 
It has been previously hypothesized that mechanical threshold testing may be 
affected by environmental or external factors (e.g. time of the day, visual stimuli, noise, 
which may cause distraction and increase the thresholds) and internal factors like 
behaviour (e.g. frightened animals or very active animals would respond earlier than calm 
and friendly animals) (Bove, 2006). In the present study behaviour significantly affected 
the mechanical thresholds obtained, with more active dogs obtaining greater threshold 
values than calm dogs. In calm dogs the device could be applied more accurately, with 
slower increasing force and it was easier to see a clear end-point than in very active dogs. 
All the evaluations were performed in a familiar room, separated from the wards, with 
minimal restraint and minimal distraction of the dogs to try to exclude the influence of 
external factors. However, some environmental factors could not be totally controlled as 
for example the time of the day when dogs were fed, which was in the morning and 
probably influenced the results. Nonetheless, behaviour was included in the model to 
account for its possible effects on the mechanical thresholds.  
 
As hypothesized, epidural magnesium
 
injection did not cause a decrease in tail 
tone or ataxia. By acting mainly on the NMDA-receptor, magnesium
 
causes analgesia, 
but it is only an exaggerated antagonistic action on the NMDA-receptor that may cause 
ataxia and motor incoordination as observed previously in rats (Bahar et al., 1996; 
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Karasawa et al., 1998). At the doses used in the present study, it seems that magnesium 
may be safely
 
added to epidural morphine without causing any motor deficits.  
 
Room temperature may affect nociception due to its effect on skin 
vasoconstriction and vasodilatation (Love, 2011). The humidity may affect the bending 
filaments, but it is unlikely to affect the rigid tips. In this study, room temperature and 
humidity were controlled and maintained relatively constant; therefore, it is very unlikely 
that they influenced the threshold readings obtained in these dogs. 
 
One limitation of this study is the fact that it was performed in dogs; therefore, 
the end-point for antinociception (i.e. withdrawal of limb or turning the head at the probe) 
is subjective and might be influenced by other factors as discussed above. Unfortunately, 
there is currently no “Gold Standard” method for antinociceptive testing in animal studies 
of pain. In this study using von Frey mechanical thresholds the antinociceptive effect of 
morphine, our positive control treatment, could be detected; therefore, it seems that the 
methodology was appropriate. 
 
Another limitation of the study is the sample size, which was limited to six dogs. 
However, by performing a cross-over study the variability is decreased; therefore, the 
statistical power is increased. The sample size was large enough to detect overall 
differences between treatments in the 3 studied regions, but it was insufficient to detect an 
onset and duration of effect of the individual treatments as previously discussed.  
 
A possible source of variability is the observer performing the testing. The intra- 
and inter-observer coefficients of variation were calculated before commencement of the 
study and they were within the range of 20-30%, which is considered acceptable for the 
validation of serological tests (Jacobson, 1998). Inter-observer variability could be 
excluded as only one person performed the measurements. The principal investigator 
performing the measurements practiced using the von Frey device before the actual study 
and learned to increase the force gradually. Therefore, this source of variability should 
have had a minimal impact on the results of this study. 
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7 Conclusion 
In conclusion, the present study showed that a lumbosacral epidural injection of 2.5 mg 
kg-1 MgSO4 produces an antinociceptive effect in dogs without causing any motor deficits 
when administered alone or in combination with morphine. The antinociceptive effect of 
magnesium could be observed in the Cp, Th and Mt indicating that antinociception 
reached up to the thoracic limbs. The onset and duration of the antinociceptive effect 
could not be determined, although a tendency could be observed. 
 
No potentiation of the antinociceptive effect could be demonstrated between 
morphine and magnesium. 
 
The von Frey aesthesiometer was able to detect the antinociceptive effects 
mediated by morphine and magnesium. 
 
To what extend these results can be extrapolated to clinical cases needs further 
investigation. As this was not a clinical trial and no clinical pain was present in these 
dogs, results obtained are not directly applicable to clinical cases with acute pain, chronic 
pain or central sensitization. Clinical studies are necessary to determine whether epidural 
administration of magnesium would be beneficial.  
 
In addition, the fact that a potentiation of the antinociceptive effect was not 
observed between morphine and magnesium contradicts the findings from the reviewed 
literature. Further studies with other type of stimuli, different dosages or performed in 
clinical cases with naturally occurring pain are warranted to demonstrate a possible 
positive interaction effect between these drugs. 
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8 Summary 
Antinociceptive effects of epidural magnesium sulphate alone or in 
combination with morphine in dogs  
 
The analgesic properties of magnesium
 
meditated by its physiological
 
antagonistic action 
on the NMDA-receptor is of great interest in human and veterinary medicine. The 
primary objectives of this study were to investigate whether the lumbosacral epidural 
injection of magnesium could produce an antinociceptive effect and to determine whether 
there was possible potentiation of the antinociceptive effect between magnesium and 
morphine when administered epidurally in combination in dogs. A secondary goal was to 
study the onset and duration of the antinociceptive effect of epidural magnesium alone or 
in combination with morphine in dogs. Furthermore, the possible motor deficits induced 
by epidural magnesium
 
were investigated. 
 
Six healthy, adult, neutered research Beagle dogs (3 male and 3 female) were 
used in a randomized blinded crossover study with a one-week wash-out period between 
treatments. Treatments consisted of an epidural injection of: 0.115 mL kg-1 of sterile 
water (treatment Co); 0.1 mg kg-1 of morphine (treatment Mo); 2.5 mg kg-1 of MgSO4 
50% (treatment Mg); and 2.5 mg kg-1 of MgSO4 together with 0.1 mg kg-1 of morphine 
(treatment Mm). Sterile water was added to treatments Mo, Mg and Mm to receive a total 
volume of 0.115 mL kg-1. Dogs were anaesthetized with propofol and isoflurane to place 
a lumbosacral epidural catheter for the administration of the treatments. Antinociceptive 
effects were evaluated at different time points for 24 hours post-injection using von Frey 
mechanical thresholds. Three threshold measurements on both sides were obtained at the 
carpal pads, thorax and metacarpi at each time point and then averaged for statistical 
analysis. Maximum applied force eliciting a nociceptive response was recorded and 
compared between treatments. Within each treatment, measurements obtained at different 
time points were compared with baseline values. Tail tone, level of ataxia, level of 
sedation and behaviour were scored at each time point. Data were analysed using a linear 
mixed model with significance set as p<0.05. 
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The treatment groups Mg, Mo and Mm had significantly higher thresholds at all 
three measured regions compared with treatment Co (except for the carpal pads with 
treatment Mm). There was a significant increase in threshold values over time obtained at 
the thorax and at all three regions pooled together. No motor deficits were observed with 
any of the treatments at any time point. Behaviour influenced the mechanical thresholds 
and was included in the statistical model as a fixed effect.  
 
In conclusion, 2.5 mg kg-1 MgSO4 administered in the lumbosacral epidural space 
in dogs produces antinociception without causing motor effects. The antinociceptive 
effect of magnesium reached up to the thoracic limbs. No potentiation of the 
antinociceptive effect could be detected between magnesium and morphine. Onset and 
duration of analgesia could not be determined although there was a significant effect of 
time on the threshold values.  
 
The present study suggests that a lumbosacral epidural injection of magnesium
 
in 
dogs might be useful to provide analgesia to the thoracic and pelvic limbs, as well as the 
thorax. However, to what extend magnesium causes analgesia in clinical cases and in 
states of central sensitisation requires further investigation. 
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9 Zusammenfassung 
Anti-nozizeptive Effekte von epidural verabreichtem Magnesiumsulfat allein 
und in Kombination mit Morphin beim Hund 
 
Die analgetische Wirkung von Magnesium
 
als physiologischer Antagonist am NMDA 
Rezeptor
 
ist von großem Interesse in der Human- und Tiermedizin. Ziel dieser Studie war 
zu untersuchen, ob die epidurale lumbosacrale Administration von MgSO4 beim Hund 
eine analgetische Wirkung besitzt und
 
ob eine Potenzierung durch gemeinsame 
Verabreichung mit Morphin erzielt werden kann. Des Weiteren wurde der Eintritt und 
die Dauer der analgetischen Wirkung von MgSO4 allein und bei gemeinsamer 
Administration mit Morphin untersucht. Das mögliche auftretenden motorische 
Funktionsausfälle wurde ebenfalls studiert. 
 
Sechs gesunde, ausgewachsene, kastrierte Beagle (3 männlich und 3 weiblich) 
wurden in einer randomisierten, blinden, „cross-over“ Studie verwendet. Die 
Auswaschzeit zwischen den verschiedenen Behandlungen betrug eine Woche. Die 
Behandlungen bestanden aus epiduralen Injektionen von: 0,115 ml kg-1 steriles Wasser 
(Gruppe Co); 0,1 mg kg-1 Morphin (Gruppe Mo); 0,005 ml kg-1 Magnesium (Gruppe Mg); 
0,005 ml kg-1 Magnesium und 0,1 mg kg-1 Morphin (Gruppe Mm). Steriles Wasser wurde 
zu den Gruppen Mo, Mg und Mm hinzugefügt, um ein absolutes Volumen von 0,115 ml 
kg-1 zu erhalten. Die Hunde wurden anästhesiert und ein Katheter, für die Verabreichung 
der Behandlungen wurde in den lumbosakral in den Epiduralraum eingeführt. Die anti-
nozizeptive Wirkung wurde zu verschiedenen Zeitpunkten über einen Zeitraum von 24 
Stunden evaluiert. Zur  Evaluierung des anti-nozizeptive Effekts wurde der mechanische 
Schwellenwertes unter zur Hilfenahmen des Von Frey Gerätes bestimmt. Jeweils drei 
Schwellenwert-Messungen an der linken und rechten Körperseite am Carpus, Thorax und 
Metatarsus wurden durchgeführt. Der maximale zugefügte Druck, der zu einer 
Schmerzreaktion führte, wurde aufgezeichnet. Die Werte wurden gruppenweise 
verglichen. Des Weiteren wurden die Werte in den Gruppen mit den Ausgangswerten 
verglichen. Zusätzlich wurde die Spannung der Rute, Grad der Sedation und das 
Verhalten der Hunde zu jedem Messzeitpunkt bewertet.  
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Die Gruppen mit der Behandlung Mg, Mo und Mm hatten signifikant höhere 
Schmerzschwellenwerte an jedem der untersuchten Körperareale verglichen mit Gruppe 
Co. Ausgenommen davon waren die Werte von MM, die kein signifikant höheren 
Schwellenwert am Carpus aufwiesen. Über den Zeitverlauf war ein signifikanter Anstieg 
des Schmerzschwellenwerts am Thorax und an allen drei gemessenen Körperareale zu 
bemerken, vorausgesetzt diese wurden gemeinsam analysiert (ausgenommen 1 Stunde 
nach der Injektion). Das Vergleichen von Schwellenwerten innerhalb jeder Gruppe zum 
jeweiligen Ausgangsschwellenwert zeigte keinen signifikanten Anstieg des 
Schwellenwertes über den Zeitverlauf. Das Verhalten der Hunde beeinflusste den 
Schwellenwert und wurde demzufolge in der statistischen Auswertung mit berücksichtigt. 
Eine Änderung der Rutenspannung trat zu keinem Zeitpunkt auf. Die Hunde waren nach 
der Anästhesie während der ersten Messungen gering bis mittelgradig sediert. 
 
Diese Studie schlussfolgert, dass MgSO4 epidural verabreicht, bei Hunden zu 
einem analgetischen Effekt führt, ohne paralytisch zu wirken. Eine synergistische 
Wirkung zwischen Magnesium
 
in der verwendeten
 
Dosis und Morphin konnte nicht 
festgestellt werden. Der Beginn und die Dauer der Analgesie konnte nicht bestimmt 
werden, wenn auch der Faktor Zeit eine Rolle zu spielen scheint.  
 
Die vorliegende Studie lässt vermuten, dass die lumbosakrale epidurale Injektion 
von Magnesium
 
zur
 
analgetischen Wirkung an der Vorder-, Hintergliedmaße und am 
Thorax führt. In welchem Umfang Magnesium
 
im klinischen Einsatz und bei zentraler 
Sensibilisierung 
 
analgetische Wirkungen vermittelt, bedarf weiteren Untersuchungen.  
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